JPH0565492B2 - - Google Patents
Info
- Publication number
- JPH0565492B2 JPH0565492B2 JP1336408A JP33640889A JPH0565492B2 JP H0565492 B2 JPH0565492 B2 JP H0565492B2 JP 1336408 A JP1336408 A JP 1336408A JP 33640889 A JP33640889 A JP 33640889A JP H0565492 B2 JPH0565492 B2 JP H0565492B2
- Authority
- JP
- Japan
- Prior art keywords
- psoriasis
- tnf
- administration
- cells
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 50
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract description 6
- 239000003085 diluting agent Substances 0.000 claims abstract description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 5
- 102000003390 tumor necrosis factor Human genes 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 abstract description 21
- 238000011282 treatment Methods 0.000 abstract description 18
- 239000000203 mixture Substances 0.000 abstract description 14
- 239000004480 active ingredient Substances 0.000 abstract description 6
- 239000003937 drug carrier Substances 0.000 abstract 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 45
- 102000057041 human TNF Human genes 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 102100040247 Tumor necrosis factor Human genes 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 230000003902 lesion Effects 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 230000000699 topical effect Effects 0.000 description 7
- 108020004511 Recombinant DNA Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- -1 at least one carrier Substances 0.000 description 6
- 239000003246 corticosteroid Substances 0.000 description 6
- 210000001339 epidermal cell Anatomy 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 229960001334 corticosteroids Drugs 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- 206010037575 Pustular psoriasis Diseases 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000001780 adrenocortical effect Effects 0.000 description 4
- 201000005884 exanthem Diseases 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 4
- 229960000907 methylthioninium chloride Drugs 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 206010037844 rash Diseases 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000011280 coal tar Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000001185 psoriatic effect Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000001126 Keratosis Diseases 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 206010043087 Tachyphylaxis Diseases 0.000 description 2
- 206010054094 Tumour necrosis Diseases 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 229940040145 liniment Drugs 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 241001517013 Calidris pugnax Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020674 Hypermetabolism Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 241001467578 Microbacterium Species 0.000 description 1
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000669298 Pseudaulacaspis pentagona Species 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex⢠Substances 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229960000190 bacillus calmetteâguérin vaccine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000000445 cytocidal effect Effects 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 229960002311 dithranol Drugs 0.000 description 1
- 230000000073 effect on psoriasis Effects 0.000 description 1
- 210000001513 elbow Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 1
- 229960002199 etretinate Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 206010018797 guttate psoriasis Diseases 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 231100001039 immunological change Toxicity 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 208000001875 irritant dermatitis Diseases 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 150000003097 polyterpenes Chemical class 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 235000011182 sodium carbonates Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011269 tar Substances 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Description
ç£æ¥äžã®å©çšåé
æ¬çºæã¯ã也ç¬ã®æ²»çã«çšããå»è¬çµæç©ã«é¢
ãããæŽã«è©³ããã¯ãããã®ä¹Ÿç¬ãæ²»çãããã
ã«æå¹æåãšããŠè «çå£æ»å åããªãã¡ãTNFã
ãå«æããå»è¬çµæç©ã«é¢ãããã®ã§ããã åŸæ¥ã®æè¡ ä¹Ÿç¬ã¯ãçœè²é±å±ã§è¢«èŠãããéå±æ§ã®çŽ æ
ãšããã°ãã°çš®ã ã®çšåºŠã®äžå¿«æã䌎ããšããã
ãšã«ãã€ãŠç¹åŸŽã¥ããããç¹æã®èšåºçç¶ã®ãã
å€ãããç¥ãããŠããæ ¢æ§ç®èçŸæ£ã§ãããæ¬çŸ
æ£ããäŒææ§ã§ã¯ãªãããšã¯æããã«ãããŠãã
ããæ¬çŸæ£ã®åå ãšæ©åºã¯ãŸã ååã«è§£æãããŠ
ããªããã¯ã«ãŒã¬ãŒããžãŒïŒãžãŒïŒïŒKrugerïŒG.
G.ïŒã也ç¬ïŒãã®ç å åŠãšçºç åŠã®æè¿ã®æŠå¿µã
ïŒâPsoriasisïŒCurrentConcepts of its Etiology
and PathogenesisâïŒã㶠ã€ã€ãŒ ãã㯠ãª
ã ããŒããããžãŒïŒThe Year Book of
DermatologyïŒïŒ1981幎ïŒããããœã³ãã¢ãŒã«ïŒ
ãšã«ïŒïŒDobsonïŒR.L.ïŒåã³ã·ã¢ãŒãºãããŒã»ãš
ããïŒïŒThiersïŒB.H.ïŒç·šéãã也ç¬ã¯ãç¬ç¹ã®
ç®èç å€åã³çºç¹ã圢æããããããã®è¢«å®³è ã«
瀟äŒç掻ãéã ãäžã§å¿ççé害ãäžããã西欧
è«žåœã§ã¯ãç·äººå£ã®çŽïŒïŒ ã也ç¬ã«çŸ æ£ããŠã
ãã 也ç¬ã¯å€å åæ§éºäŒçŸæ£ããããéºäŒççŽ å ã
èæ¯ã«ããããææãè¬ç©ãé£ç©ã颚åãã¹ãã¬
ã¹ãªã©ã®çš®ã ã®ä»ã®å åã®äœçšã«åºæ¿ããçºçã
ããšèããããŠããããããã®å åã®ãããã®ã
ãããã¯å šãŠããã®éºäŒççŽ å ã®åŒãéãšãªãåŸ
ãã也ç¬ããçµç¹é©åæ§æåïŒHLAïŒéºäŒåã®
å€æ§æ§ã«åºã¥ããŠå€åœ¢çŸè±¡ã瀺ãHLAãšå¯æ¥ã«
é¢é£ããŠããããšãç¥ãããŠããã®ã§ã也ç¬ãéº
äŒæ§çŸæ£ã§ããããšã¯æããã§ããã 也ç¬ç å€ã®çºçãšãã®å¯è§£ã¯ããã°ãã°äº€äºã«
æ°å¹Žéã«ãããçµéšãããã也ç¬ã«ã¯ïŒã€ã®ç¹åŸŽ
ççç¶ããããããªãã¡ãä»ã®è¡šåšæ§ç®èçŸæ£ãš
å ±éããççåå¿ãåã³è¡šç®ã®ç°åžžå¢æ®ååã§ã
ããå€ãã®ç 究è ãã¡ã¯ããã®ççåå¿ã®æ©åºã
å ç«åŠçåŽé¢ããããããŠè¡šç®ã®ç°åžžå¢æ®åŸåã®
æ©åºã现èççåŠçåŽé¢ãã解æããããšåªããŠ
ãããããã®æ©åºã¯ããŸã ååã«è§£æãããŠããª
ããããŠãŒãããŒãã€ãŒã»ãšããïŒBeutnerïŒE.
H.ïŒãã也ç¬ã«ãããèªå·±å ç«ãïŒâAutoimmunity
in PsoriasisâïŒãã·ãŒã¢ãŒã«ã·ãŒ ãã¬ã¹ïŒCRC
PressïŒãããŒã« ã©ãŒãã³ïŒBoca RatonïŒã
1982幎ãã 也ç¬ã¯ãç®èã®ççæ§è§åã䌎ãçŸæ£ã®ãã¡å ž
åçãªçŸæ£ã§ããã也ç¬ã«çœ¹æ£ããæ£è ã®æ°ã¯å¢
å ãã€ã€ããã也ç¬ã«å¯ŸããŠçš®ã ã®åé¡ããªãã
ãŠããããäžè¬ã«ã¯ãå°åžžæ§ä¹Ÿç¬ãè¿ç±æ§ä¹Ÿç¬ã
é¢ç¯çæ§ä¹Ÿç¬ã滎ç¶ä¹Ÿç¬ãªã©ã«åé¡ãããããã
ãã®ç åã®ãã¡å°åžžæ§ä¹Ÿç¬ãäž»èŠãªã¿ã€ãã§ãæ¬
çŸæ£ã®å šäŸã®80ïŒ ãã90ïŒ ãå ããã也ç¬ã«çœ¹æ£
ãããšãæ確ãªå¢çããã€ãçŽ æãããã¯çŽ è²äž
ç¹ãå€éšããã®èµ·çæ§åºæ¿ãåããããäœã®éš
åãäŸãã°ãé éšãèãèãèéšãªã©ã®éšåãã
现èããã³ãç¹æ®ããããææ¯éšåãªã©ã«çã
ãã 也ç¬ã«é¢ããŠããã®ç å€éšäœã«ããã圢æ åŠç
å€åã®ç¹åŸŽã«é¢ããäžè¬çãªç 究ããã®ç å€éšäœ
ã«ãããçååŠçãå ç«åŠçå€åã®ç¹åŸŽã«é¢ãã
ããæè¿ã®ç 究ãå«ããŠããŸããŸãªç 究ããªãã
ãŠããããããã«ããããããã也ç¬ã®æ ¹æ¬çå
å ã也ç¬ç å€ã®çºçæ©åºã¯ãããŸã 解æãããŠã
ãªãã也ç¬ã®å šãŠã®ã¿ã€ãã«ãããŠãæ§ã ã®çç¶
ãçŸè±¡ã芳å¯ãããŠãããããšãã°ã代è¬äº¢é²ã«
ãã现èã®é床ã®å ¥ã代ãã«ããè¡šç®çŽ°èã®è¥å
ãè§åç°åžžãè¡šç®ä¹³é å±€ã«ãããççåå¿ã®èã
ã亢é²ãçç®ã«ãããè¡ç®¡æ¡åŒµãšéèèè¡ããã³
è¡šç®çŽ°èå±€ãžã®å€æ žçœè¡çã®éèµ°ãšæµžæœ€ã芳å¯ã
ããã å»åž«ãã¡ã«ãã€ãŠåŸæ¥çšããããŠãã代衚çãª
也ç¬æ²»çæ³ã¯è¡šç®çŽ°èã®æ©èœäº¢é²æ§å¢æ®ãå¶åŸ¡ã
ãããšãççåå¿ãæå¶ããããšãå ç«èª¿ç¯ãä¿
é²ããããšãããã³çŽ°èããã³ã«ããææãé²ã
ããšã§ãããããšãã°ã以äžã®æ²»çæ¹æ³ãåŸæ¥çš
ããããŠããã (1) å¯è ç®è³ªãã«ã¢ã³ã®å€çšåã³å çš å¯è ç®è³ªãã«ã¢ã³ã®ãããªã¹ããã€ãã®å€çšã
ããã¯å±æç䜿çšã¯ã也ç¬ã®çç¶ã軜æžããå³æ
å¹æãç¹ã«çºç¹ã軜æžããå¹æãæãããããã®
æ²»çã®ããã«ã¯é·æéã«ãããå¯è ç®è³ªãã«ã¢ã³
ã®æäžãå¿ èŠã§ãããé·ææäžã¯ã¿ããã€ã©ãã·
ãŒçŸè±¡ïŒTachyphylaxisïŒãå³ã¡æ £ãã®çŸè±¡ãåŒ
ãèµ·ããããã®ãããæãŸããæ²»çå¹æãåŸãã
ãã«ã¯çšéã®å¢å ããããã¯ãã匷ãè¬ç©ã®äœ¿çš
ãå¿ èŠãšãªããææãå¯è ç®è³ªãã«ã¢ã³ã«ãã€ãŠ
æ²»çããéšäœã«æ°ããç å€ã®çºçã芳å¯ããããš
ããããå¯è ç®è³ªãã«ã¢ã³ããã³ãŒãã€ã³ã°å€ã
è»èãå¡åžå€ã®åœ¢æ ã§ç®èã«æäžããå Žåãå¯è
ç®è³ªãã«ã¢ã³ã®äœçšã¯ãç å€éšäœã ãã§ã¯ãªãåš
å²ã®æ£åžžãªç®èã«ãåã³ããã®æ£åžžéšäœã«ãããŠ
çç®ã®èçž®ãšèŒçœåããããã¯ã¹ããã€ã座ç¡ã
åŒãèµ·ããããã ããã«ãå¯è ç®è³ªãã«ã¢ã³ã®å¯äœçšãé¿ããã
ãããã®ãã«ã¢ã³ã®æäžãäžæ¢ãšãããšãåè·³çŸ
象ãšããŠç®èçããã°ãã°çããããç å€ã¯æ¡å€§
ãæªåããåŸåã«ããããã®ãããªåè·³çŸè±¡ãšã
ãŠçããç®èçã¯ãç¹ã«ãå æè¬ã®æäžãäžæ¢ã
ãå Žåã«èµ·ããããããåŸã€ãŠãç å€ãç®èã®æ¯
èŒçåºãéšäœã«ã¿ãããå Žåããã®æ¹æ³ã ãã§å®
å šã«æ²»çããããšã¯ã§ãããä»ã®æ²»çæ³ãšã®äœµçš
ãå¿ èŠã§ããã (2) å ååŠçæ³ ãã®æ¹æ³ã¯ããœã©ã¬ã³ïŒpsoralenïŒãå€çšå€ã
ããã¯å æè¬ã®åœ¢æ ã§æäžãã次ãã§é·æ³¢é·ã®çŽ«
å€ç·ãæ£éšã«ç §å°ããããšãããªããããããã
ã®æ¹æ³ã§æ²»çã§ããªãã¿ã€ãã®ä¹Ÿç¬ãããããã
ã«æ¥å çæ³ãšåæ§ã«ãã®çæ³ãé·æéè¡ãªããšã
ç®èã«èåã«äŒŒãçŸè±¡ãèµ·ããã ãã§ãªããç¹åŸŽ
çãªè²çŽ æã®åœ¢æãèµ·ãããããã (3) å çæ³ïŒUVç §å°ïŒ æ¥å çæ³ã®å Žåãšåæ§ã«ã玫å€ç·ç §å°ãé·æé
å®æœãããšãç®èã®èåä¿é²ãåŒãèµ·ããããã
ãã§ãªããçºçã®èªçºãèµ·ããåŸãã (4) ã³ãŒã«ã¿ãŒã«ã®å€çšçæ³ ã³ãŒã«ã¿ãŒã«ã¯è¡šç®çŽ°èã®æé·ãæå¶ããã®
ã§ãç å€ãçæéã«æ¶å€±ããæ¯èŒçé·ãå¯è§£æé
ãéæããããããããæãšããŠãåºæ¿æ§ç®èç
ãæ¯ãçïŒã¿ãŒã«åº§ç¡ïŒãåŒããããããããšã
ããã (5) ã¡ããã¬ãã»ãŒãïŒmethotrexateïŒã®æäž ã¡ããã¬ãã»ãŒãã¯ãèé žã«å¯Ÿããæ®æç©è³ª
ã§ã现èã®æé·ãæå¶ããäœçšããããã¡ããã¬
ãã»ãŒãã®äœ¿çšã¯ãè¿ç±æ§ä¹Ÿç¬ã®æ²»çã«å¹æãã
ãããé·æéæäžãããšãèæ©èœé害ã骚é«æå¶
ãªã©ã®å¯äœçšãèµ·ããã (6) ã¬ããã€ãïŒretinoidïŒã®æäž ã¬ããã€ãã¯å ç«èª¿ç¯äœçšãæãããšèããã
ãŠãããããªãã¡ãã¬ããã€ãã¯è¡šç®çŽ°èã®ç°åžž
è§åãšçœè¡çéèµ°ã®æ©èœäº¢é²ãæå¶ããããšãã¬
ãããŒãïŒetretinateïŒã®ãããªã¬ããã€ãã®å
ææäžã¯è¿ç±æ§ä¹Ÿç¬ãšä¹Ÿç¬æ§çŽ ç®çã®æ²»çã«ç¹ã«
å¹æçã§ãããããããªããããã°ãã°ç®èãå¯
èŠç²èã®åããèããªããšããå¯äœçšãããããŸ
ããè¡æž ãªãã¿ã³ãã¯æ¿åºŠã®ç°åžžããã°ãã°èŠ³å¯
ããããããã«ãã¬ããã€ãã«ã¯å¬å¥åœ¢æ§äœçšã
ãããäœå ã«èç©ãããããåãé·æéäœå ã«æ®
çããåŸåã«ããããã®ãããåŠåš å¯èœãªå¥³æ§ã«
ã¬ããã€ãã䜿çšããããšã¯é¿ããã¹ãã§ããã
åŸã€ãŠãéåžžãã¬ããã€ãã¯ãåŠåš å¯èœãªå¹Žéœ¢ã
éãã女æ§æ£è ããããã¯é£æ²»æ§ä¹Ÿç¬ã«çœ¹æ£ããŠ
ããæ£è ã®ã¿ã察象ã«ããŠçšããããã äžèšã®ããã«ãå¯è ç®è³ªãã«ã¢ã³ã¯ãããçšåºŠ
也ç¬çç¶ã軜æžããå³æå¹æã瀺ãããã¿ããã€
ã©ãã·ãŒçŸè±¡ãèµ·ããããããããã®ãã«ã¢ã³ã
é£ç¶æäžããããšãå°é£ã§ãããããã«å¥œãŸãã
ãªãããšã«çšéãå¢å ããªããã°ãªããªããªãã
ãã®ãããªå ŽåãäŒè¬ãããããããã¯å¯äœçšã
é¿ãããããã®ãã«ã¢ã³ã®æäžãäžæ¢ãããšãã
ã°ãã°åè·³çŸè±¡ãšããŠç®èçããããçç¶ããã
ã«æªåãããåŸã€ãŠãå¯è ç®è³ªãã«ã¢ã³åç¬ã§å¹
æçã«ä¹Ÿç¬ãæ²»çããããšã¯é£ãããå ååŠçæ³
ããã³ãŒã«ã¿ãŒã«ãã¢ã³ã¹ã©ãªã³ïŒanthralinïŒã
ã¬ããã€ããªã©ã®è¡šç®çŽ°èå¢æ®æå¶å€ã䜿çšãã
çæ³ãå¯è ç®è³ªãã«ã¢ã³ãšäœµçšãããšãããçšåºŠ
ã®æ²»çå¹æã¯éæã§ãããããããªããã也ç¬ã
å®å šã«æ²»çããããšã¯ã§ããªãããã¬ããŒã¯ããš
ããïŒãšããïŒïŒãžãšãŒã¢ãŒã«ïŒRoenigkïŒH.
H.ïŒJr.ïŒåã³ãã€ã³ãããããšããïŒã¢ã€ïŒ
ïŒMainnbachïŒH.I.ïŒãããœã©ã€ã¢ã·ã¹
ïŒPsoriasisïŒãããŒã»ã«ããã«ãŒç€ŸïŒMarcel
Dekker Inc.ïŒãããŠãŒãšãŒã¯ã1985幎ãã çºæã解決ããããšããèª²é¡ åŸã€ãŠãæ¬çºæã®ç®çã¯ã也ç¬æ²»çã«æå¹ãªæ°
èŠå»è¬çµæç©ãæäŸããããšã«ããã æ¬çºæã®å¥ã®ç®çã¯ãçŸåšç¥ãããŠããçµæç©
ã®ãã€æ¬ ç¹ãå®è³ªäžãªã也ç¬æ²»çã«æå¹ãªå»è¬çµ
æç©ãæäŸããããšã«ããã 課é¡ã解決ããããã®æ段 æ¬çºæã®äžèšã®ç®çã¯ãæ¬çºæè ãã®çºèŠã
ããå ¬ç¥ã®æ²»çè¬ãæ²»çæ¹æ³ã«äžå¯é¿çã«äŒŽãäž
èšã®æ¬ ç¹ãæããªãæ°ããã¿ã€ãã®å»è¬çµæç©å
ã³ãã®å»è¬çµæç©ã也ç¬ã®æ²»çã«çšããæ¹æ³ã«ã
ã€ãŠéæãããããã®çºèŠãšã¯è©³ããã¯ãè «çå£
æ»å åãããªãã¡TNFããå ¬ç¥ã®åŠäœãªãæ²»ç
è¬ãæ²»çæ¹æ³ã§ãæ²»çã§ããªãã€ã也ç¬æ£è ã«æ
äžãããšãçç¶ãå šèº«ããæ¶å€±ãããšããããšã§
ããã æ¬çºæã«ããã°ã也ç¬æ²»çã«æå¹ãªéã®TNF
ãšå°ãªããšãäžçš®ã®å»è¬æäžå¯èœãªæ äœãåžéå€
ãããã¯è³Šåœ¢å€ãå«æãã也ç¬æ²»ççšã®æ°èŠå»è¬
çµæç©ãæäŸãããããã也ç¬æ£è ã®æ²»çã«çšã
ãããæ¬çºæã®å»è¬çµæç©ã«ãããŠã¯ãè «çå£æ»
å åã¯ãããç±æ¥ã®çŽ°èããããããã¯çµæã
DNAæè¡ã«ãã€ãŠè£œé ããããã®ã§ããããšã
奜ãŸããããã®ãããªçµæç©ã«ã¯ãäŸãã°ãéè
å 泚å°çšãçèå 泚å°çšãç®äžæ³šå°çšãç®å 泚å°
çšãçµå£æäžçšãçŽè žå æäžçšãå€éšæœçšçšãå±
ææœçšçšãç¹çŒçšãªã©ã«é©åããæäžåœ¢æ ãäžã
ãããšãã§ãããããã«ãæ¬çºæã®å»è¬çµæç©ã¯
ããªããããçµæç©ã«é©åããæäžåœ¢æ ãäžãã
ããšãã§ããã è «çå£æ»å åãããªãã¡TNFã¯ãçåèœåã®
ãããã€ã¯ããã¯ããªãŠã ããŒãã¢ã€ã¹
ïŒMicrobacterium boviceïŒã®ããã«ã¹ã«ã«ã¡
ãããŒã°ãšãªã³ïŒBacillus CalmetteâGuerinïŒ
æ ªïŒBCGïŒãåæäžåŸã现èã®ãšã³ãããã·ã³
ãéèå æäžããããŠã¹ã®è¡æž äžããåããŠçºèŠ
ããããããã·ãŒãã€ã³ã°ã¹ã»ãªãã»ãã·ãšã
ã«ã»ã¢ã«ãããŒã»ãªãã»ãµã€ãšã³ã¹ã»ãŠã»ãšã¹ã»
ãšãŒïŒProc.Nat.Acad.Sci.U.S.A.ïŒ72巻第ïŒå·ã
3666â70é ïŒ1975幎ïŒããTNFãå«æããããŠã¹
è¡æž ã¯ãin vitroè©Šéšã§å€æ°ã®ããŠã¹åã³ãã
圢質転æ现èç³»ã«å¯ŸããŠçŽ°èå·å®³æŽ»æ§äœçšããã
ã¯é现è掻æ§ã瀺ããããããã®äœçšã¯æ£åžžçŽ°è
ã«å¯ŸããŠã¯éåžžã«åŒ±ããTNFãå«æããããŠã¹
è¡æž ã¯ãããŠã¹ã«ç§»æ€å¯èœãªè «çã®å£æ»ãçãã
ããããTNFã¯ã©ãããã«ãµã®åã³ã¢ã«ã¢ãã
ã®è¡æž äžã«ãç£çãããããã«ãTNFã¯åºä¹³é¡
ç±æ¥ã®åæ žé£çŽ°èãç¹ç¶èœçŽ°èã现èãªã©ã«ã
ã€ãŠãããæ¡ä»¶äžã«ãããŠç£çããåŸããã®ã§ã
ããããã«é¢ããŠã¯ããã€ã ãžãšã€ïŒãªãŒã«ã
ïŒLloyd J.OldïŒã«ãã€ãŠãµã€ãšã³ãã€ãã€ãã¯
ã¢ã¡ãªã«ã³ïŒScientific AmericanïŒ258巻第ïŒ
å·59â75é ïŒ1988幎ïŒæïŒã®ç·èª¬ã«åŒçšãããæ
ç®äžã«å€ãã®å ±åããããæ¬çºæã«ãããŠã¯ãåº
ä¹³é¡ç±æ¥ã®è¡æž ãããã¯åºä¹³é¡ç±æ¥ã®çŽ°èããåŸ
ãããäžèšTNFã掻æ§æåãšããŠçšããããšã
ã§ãããæ¬çºæã®å¥œãŸããæ æ§ã«ãããŠã¯ãå ç«
é©åæ§çã®ç¹ããããŠãå°ãªããšãããTNFã
å«æããå»è¬çµæç©ãçšããããšã奜ãŸããã åèšããTNFã¯ãçµæãDNAæè¡ã«ãã€ãŠè£œ
é ããããšãã§ããããããç±æ¥ã®çŽ°èãå¹é€ã
ãããšã«ãã€ãŠã補é ããããšãã§ããã çµæãDNAæè¡ã«ããããTNFã補é ããã«
ã€ããŠã¯ãããšãã°ãã·ã©ã€ ãã€ãŒïŒïŒShirai
T.ïŒããããŒãã€ãŒïŒNatureïŒã313å·»803â806
é ïŒ1985幎ïŒãç¹éæ60â252496å·ïŒæ¬§å·ç¹èš±åº
é¡å ¬éç¬¬ïŒ 158 286å·ã«å¯Ÿå¿ïŒã«èšèŒãããŠã
ãæ¹æ³ãæ¡çšã§ããããããã®æç®ã«èšèŒããã
æ¹æ³ã«ããã°ãäŸãã°ãå€§è žèã®å¹é€ã«ãã€ãŠå
質ãªããTNFãå¹ççã«åŸãããšãã§ããã äŸãã°ã次ã®ããã«ããŠåèšããTNFã補é
ããããšãã§ãããããªãã¡ã50ÎŒïœïŒmlã®ã¢ã³
ãã·ãªã³ãå«æããã«ãªã¢å¹å°ïŒLuria brothïŒ
äžã§å¹é€ããå€§è žèK12ïŒD1212ïŒïŒpHNtac4ã®
èäœãé å¿åé¢ã«ãã€ãŠéãã10åãã³ãã³âãŽ
ãŒãªã³ãã¬ã¹ïŒMantonâGaulin pressïŒããŽãŒ
ãªã³ç€ŸïŒGaulin CO.ïŒè£œãç±³åœããéãæ¿Ÿéã
ããäžæž ãšããŠåŸããã现è溶è液ã¯ãã¿ã³ãã¯
質ïŒmgåœã32000åäœã®æ¯æŽ»æ§ãæã€ããã®çŽ°è
溶è液ã20mMããªã¹âå¡©é žç·©è¡æ¶²ïŒPH8.0ïŒã§
平衡åããDEAEã»ãã¢ããã¯ã¹CLâ6Bã«ã©ã
ïŒãã¢ã«ãã·ã¢ç€Ÿè£œãã¹ãŠãšãŒãã³ïŒã«ããã
100mMå¡©åãããªãŠã ãå«ã20mMããªã¹âå¡©
é žç·©è¡æ¶²ãçšããŠPH8.0ã§æº¶é¢ãããâ现èå·
害掻æ§ãæã€ç»åãããŒã«ããããã«éçååé
ã®6000ã®ããªã¹ã«ãã³ããªããŒãã¢ã€ããŒ
ïŒpolysulfone hollow fiberïŒæåææ ªåŒäŒç€Ÿè£œïŒ
ãçšããŠæ¿çž®ããããã®æ¿çž®æ¶²ã60âã§30åéé
ãã«æªæããªããå ç±ãã0.2ÎŒmèïŒãããŒã©ã
ã©ããªãŒç€Ÿè£œãç±³åœïŒãçšããŠæ¿Ÿéããããã®ãµ
ã³ãã«ã150mMå¡©åãããªãŠã ãå«ã20mMã
ãªã¹âå¡©é žç·©è¡æ¶²ïŒPH8.0ïŒã§å¹³è¡¡åããå¥ã®
DEAEâã»ãã¢ããŒã¹GLâ6Bã«ã©ã ïŒ2.6Ã11
cmïŒã«ããã掻æ§ç©è³ªã150mMå¡©åãããªãŠã
ãå«ã20mMããªã¹âå¡©é žç·©è¡æ¶²ïŒPH8.0ïŒã§æº¶
é¢ãã掻æ§ç»åãããŒã«ããããã®æŽ»æ§ç»åã
150mMå¡©åãããªãŠãã ãå«ã5mMãªã³é žãã
ãªãŠã ïŒPH7.4ïŒäžã§ã»ãã¢ã¯ãªã«ïŒ³â200ã«ã©ã
ïŒãã¢ã«ãã·ã¢ç€Ÿè£œãã¹ãŠãšãŒãã³ïŒã«ãããã
掻æ§ç»åã¯ååé45000ã®ç»åã«çžåœããTNF掻
æ§ã®ååçã¯41ïŒ ã§ããã ãã®ããã«ããŠåŸãããããTNFã¯ã¿ã³ãã¯
質ïŒmgåœãçŽ1.4Ã106åäœã®æ¯æŽ»æ§ãæãã
BALBïŒïœããŠã¹ã®è ¹è å ã«ç§»æ€ããã¡ã¹ïŒ¡è
è «ã®åºè¡æ§å£æ»ãèªçºããããã®TNAã¯ãŸã å®
å šã«ã¯ç²Ÿè£œãããŠããªããåŸã€ãŠãå¿ èŠã«å¿ããŠ
ããé«çŽåºŠã®ããTNFãåŸãããã«äžèšã®æè¡
ãåç¬ã§ããããã¯çµåããŠããã«ç²Ÿè£œããããš
ãã§ããããªããããTNF掻æ§ã¯ãâïŒçŽ°è
ãã¢ã¡ãªã«ã³ ã¿ã€ã ã«ã«ãã€ãŒã³ã¬ã¯ã·ãšã³ã
ã·ãŒã·ãŒãšã«1.2ïŒAmerican Type Culture
CollectionïŒCCL1.2ïŒããçšãããŠã€ãªã¢ã ãœã³
çïŒWilliamson etal.ïŒã®æ¹æ³ã®å€æ³ã«ããããŠ
ã¹ïŒ¬â现èã«å¯Ÿãã殺现è掻æ§ã«ãã€ãŠç¥ãããš
ãã§ãããã¢ã¹ ããŒïŒïŒMoss B.ïŒãããã·ãŒã
ã€ã³ã°ã¹ã»ãªãã»ãã·ãšãã«ã»ã¢ã«ãããŒã»ãª
ãã»ãµã€ãšã³ã¹ïŒãŠãŒïŒãšã¹ïŒãšãŒïŒProc.Nat.
Acad.Sci.U.S.A.ïŒ80å·»5397â5401é ïŒ1983幎ïŒãã
çå现èæ°ã¯ã©ãïŒRuffïŒãšã®ããªãŒã
ïŒGiffordïŒã®å 床枬å®æ³ã«ãã€ãŠæž¬å®ããããžã€
ãŒãã« ãªã ã€ã ãããžãŒïŒJ.Immun.ïŒ125å·»
1671â1677é ã1980幎ãã åèšããTNFã¯ãäžè¿°ããæ¹æ³ä»¥å€ã«ããã€
ã¢ã³ ããã«ïŒDiane PennicaïŒããããŒãã€ãŒ
ïŒNatureïŒã312å·»ã20â27é ïŒ1984幎12æïŒã«èš
èŒããæ¹æ³ãã欧å·ç¹èš±åºé¡å ¬é第168214å·åã³
第155549å·ãªã©ã«èšèŒãããŠããä»ã®å ¬ç¥ã®æ¹æ³
ã«ãã€ãŠã補é ããããšãã§ããã ããTNFãæ§æããã¢ããé žã®æ°ã¯ãTNFã
åŸããããã«çšãã補é æ¹æ³ã«ãã€ãŠç°ãªããã
ãšãã°ãç¹éæ60â252496å·ã«èšèŒãããŠããçµ
æãDNAæè¡ã«ãã€ãŠè£œé ãããããTNFã¯
155åã®ã¢ããé žããæããäžæ¹ãäžèšã®ããã«
ïŒPennicaïŒçã®æ¹æ³ã«ãã€ãŠè£œé ããããã
TNFã¯157åã®ã¢ããé žããæããäžèšã®155å
ã®ã¢ããé žãšããã®ïŒ®æ«ç«¯ã«çµåããïŒåã®ã¢ã
ãé žãããªãé åãæããã çµæãDNAæè¡ã«ãã€ãŠè£œé ãããTNFã¯ã
äžèšã®ã¢ããé žé åã®ïŒ®æ«ç«¯ã«ã¡ããªãã³æ®åºã
çµåããŠããããªãããããšãäžèšã®ã¢ããé žé
åã®ïŒ®æ«ç«¯ã«ããTNFã®ãžã°ãã«ããããã®äž
éšåãããã¯å šéšãçµåããŠããäžéäœãå å«ã
ããèªç¶ã®å€ç°ããããã¯äººçºçå€ç°ã«ãã€ãŠã
ãã®ããªããããã®æŽ»æ§ã«ææãªå€åãçããã
ãšãªãããªãããããã³ãŒãããDNAã®æ§é ã®
äžéšãå€ããããšã¯å¯èœã§ããã æ¬çºæã§çšããããšã®ã§ããããTNFã¯ãäž
èšã®ã¢ããé žé åãæããããªããããã®çžåå€
ç°äœïŒhomologous variantïŒã«çžåœããæ§é ã
æããããªãããããå å«ãããçžåå€ç°äœã®äŸ
ãšããŠãç±³åœç¹èš±ç¬¬4677063å·ãšç¬¬4677064å·ã«èš
èŒãããŠãããããããæãããããã®é瀺å 容
ã¯ãåç §ã«ãã€ãŠæ¬æ现æžã«èšèŒããããããã
ã¹ãŠã®çç掻æ§ãããããã以äžãããTNFã
ãšç§°ããã 倩ç¶ã®ããTNFã¯ãçååŠç修食ãããã¯å
åŠç修食ãåãæãããŸããïŒéäœãïŒéäœã®ã
ããªäŒåäœã®åœ¢ã«ãªãæããããããªããããã
ãã®TNFããªããããããŸããæ¬çºæã®å»è¬çµ
æç©ã®æŽ»æ§æåãšããŠäœ¿çšã§ããã æ¬çºæã®å»è¬çµæç©ã¯ãåºæ¬çã«ã¯äžè¿°ããè «
çå£æ»æŽ»æ§ãæããTNFãæå¹æåãšãããã®
ã§ããããä»ã®è «çå£æ»æŽ»æ§ãæããç©è³ªãäŸã
ã°ãªã³ãããã·ã³ãçµæç©äžã«å«æããããŠãã
ãã æ¬çºæã®å»è¬çµæç©ã¯ãäŸãã°ãéèå 泚å°ã
çèå 泚å°ãç®äžæ³šå°ãç®å 泚å°ãçµå£æäžãçŽ
è žå æäžãå€çšããããã¯ç¹çŒçšçã«é©ããçš®ã
ã®è£œå€ã®åœ¢æ ã«èª¿è£œããããšãã§ãããæ¬è£œå€ã¯
ããªããããçµæç©ã®æäžã«é©åãã圢æ ã«èª¿è£œ
ããã®ãæçšã§ããã æ¬çºæã®å»è¬çµæç©ã調補ããã«éããæ¬çºæ
ã®å»è¬çµæç©ã«çš®ã ã®æ·»å ç©ãäŸãã°ãå°ãªããš
ãïŒçš®ã®æ äœãåžéå€ã賊圢å€ãæµåå€ãçµå
å€ãå®å®åå€ãå¢ç²å€ãPH調æŽå€çãé©å®å ãã
ããšãã§ããã 奜é©ãªæ äœãåžéå€åã³è³Šåœ¢å€ãšããŠã¯ããžã€
ã¬ã€ã¢æŸ±ç²ãããŠã¢ãã³ã·æŸ±ç²ãããã¹ããªã³ã
å°éºŠæŸ±ç²ãããããã·ãããã«æŸ±ç²çã®æŸ±ç²é¡ã
ä¹³ç³ããããŠç³ãã·ãšç³ããã³ããŒã«ããœã«ãã
ãŒã«çã®ç³é¡ãã¡ãã«ã»ã«ããŒã¹ãã«ã«ããã·ã«
ã¡ãã«ã»ã«ããŒã¹ããã³ããããã·ãããã«ã»ã«
ããŒã¹çã®ã»ã«ããŒã¹é¡ãå¡©åãããªãŠã ãããŠ
é žãç¡«é žã«ã«ã·ãŠã ããªã³é žã«ã«ã·ãŠã ãæ²éç
é žã«ã«ã·ãŠã çã®ç¡æ©ç©ãæããããã 奜é©ãªæµååå€ãšããŠã¯ãé žåãã°ãã·ãŠã ã
åæã±ã€é žã¢ã«ãããŠã ãã¡ã¿ã±ã€é žãã¢ã«ãã³
é žãã°ãã·ãŠã ãå«æ°Žã±ã€é žãç¡æ°Žã±ã€é žãã¿ã«
ã¯ãã¹ãã¢ãªã³é žãã°ãã·ãŠã ãã«ãªãªã³çãæ
ããããã 奜é©ãªçµåå€ãšããŠã¯ãããªãšãã¬ã³ã°ãªã³ãŒ
ã«ãããªããã«ãããªãã³ãããªããã«ã¢ã«ã³ãŒ
ã«ãã¢ã©ãã¢ãŽã ããã©ã¬ã³ããã¢ã«ã®ã³é žãã
ãªãŠã ããŒã©ãã³ãã°ã«ãã³çãæããããã 奜é©ãªå®å®åå€ãšããŠã¯ãã¢ã«ããã³ãããã¿
ãã³ããŒã©ãã³ãã°ã«ããªã³ãªã©ã®ã¿ã³ãã¯è³ªã
ã¢ããé žåã³ãã®å¡©é¡ãªã©ãæããããã 奜é©ãªå¢ç²å€ãšããŠã¯ãã·ãšç³ãã°ãªã»ãªã³ã
ã¡ãã«ã»ã«ããŒã¹ãã«ã«ããã·ã¡ãã«ã»ã«ããŒã¹
çãæããããã 奜é©ãªPH調æŽå€ãšããŠã¯ãå¡©é žãæ°Žé žåãããª
ãŠã ããªã³é žå¡©ãã¯ãšã³é žå¡©ãçé žå¡©çãæãã
ããã æ¬çºæã®å»è¬çµæç©ãé å€ã®åœ¢æ ã®å Žåã¯ãäž
èšã®å®å®å€ã«å ããä¹³ç³ãã©ã¯ããŒã¹çã®æ äœã
æ·»å ããããšãã§ããã æ¬çºæã®å»è¬çµæç©ã¯å¡åžå€ãè»èãã¯ãªãŒ
ã ããããã¯å±ææäžã«é©ããä»ã®è£œå€åœ¢æ ãäŸ
ãã°ãšã¢ããŸã«ã湿åžå€ãããå€ãªã©ã®ãããã®
圢æ ã«èª¿è£œããŠçšããŠç®èãžã®æå¹æåã®æµžéã
ä¿é²ããããšãã§ããããã®ãããªå Žåãçé¢æŽ»
æ§å€ãç²çå€ãæ²¹æ§åºå€çãæ·»å ããããšãã§ã
ãã 奜é©ãªçé¢æŽ»æ§å€ãšããŠã¯ãã©ãŠãªã«ç¡«é žãã
ãªãŠã ãããŠã€ãŒã³ïŒTweenïŒç³»çé¢æŽ»æ§å€
ïŒããªãªãã·ãšãã¬ã³ã°ãªã³ãŒã«ãœã«ãã¿ã³ã¢ã«
ãã«ãšã¹ãã«é¡ïŒãã¹ãã³ïŒSpanïŒç³»çé¢æŽ»æ§å€
ïŒã¢ã·ã«ãœã«ãã¿ã³ïŒçãæããããã 奜é©ãªç²çå€ãšããŠã倩ç¶ãŽã ãããã«ãŽã ã
ããªã€ãœããã¬ã³ãããªã¢ã«ãã«ã¢ã¯ãªã¬ãŒãã
ããªãã«ãã³æš¹èçãæããããã 奜é©ãªæ²¹æ§åºå€ãšããŠã¯ãé«çŽèèªæã¢ã«ã³ãŒ
ã«ãé«çŽèèªé žãšã¹ãã«ãããŠãããªã°ãªã»ã©ã€
ããã¢ãã°ãªã»ã©ã€ããæµåãã©ãã€ã³ãã¢ã€ãœ
ããŒïŒã³ãã©ãã€ããŒãïŒãã¯ã»ãªã³ç³æ²¹ãŒãªãŒã
ïŒãããã©ã¿ã ïŒãã·ãªã³ã³æ²¹ããã©ããªã³ãæ¹è¯
æ€ç©æ²¹ãããã·æ²¹ã®ãããªå€©ç¶æ²¹çãæããã
ãã æ¬çºæã®å»è¬çµæç©ã¯ãæ人ã«å¯ŸããTNFã®
äžæ¥æäžéãšããŠãäžè¬ã«çŽ50ãã100000000å
äœã®çšéã§ã奜ãŸããã¯ãå±ææäžã®å Žåã«ã¯ã
çŽ50ãã500000åäœã®çšéã§ãéèå æäžãçè
å æäžã®ãããªäžè¬çãªæäžã®å ŽåãçŽ1000ãã
10000000åäœã®çšéã§ããããŠçµå£æäžã®å Žåã«
ã¯ãçŽ10000ãã100000000åäœã®çšéã§ä¹Ÿç¬æ£è
ã«æäžããããšãã§ãããäžæ¥ã®æäžéã¯ãæ£è
ã®çç¶ã«å¿ããŠå¢æžã§ããã äžèšã«ãããŠçšãããïŒåäœïŒïŒµïŒãã¯ïŒmlåœ
ãïŒÃ105åã®ïŒ¬âïŒçŽ°èãã¢ã¡ãªã«ã³ ã¿ã€ã
ã«ã«ãã€ãŒ ã³ã¬ã¯ã·ãšã³ ã·ãŒã·ãŒãšã«1.2
ïŒAmerican Type Culture Collection CCL1.2ïŒã
ã®50ïŒ ã殺ãTNFã®éãæå³ããããã®éã¯æ¬¡
ã®ããã«ããŠæž¬å®ã§ãããããªãã¡ãå¹é€å®¹åšãš
ããŠã96ç©Žã®çµç¹å¹é€çšãã€ã¯ããã¬ãŒãïŒãã
ãŒã©ãã©ããªãŒç€Ÿè£œãç±³åœïŒãçšããâïŒçŽ°è
ã1vïŒïœïŒ ã®ãŠã·èå è¡æž ãå«ãã€ãŒã°ã«
ïŒEagleïŒã®ãããã ã»ãšãã»ã³ã·ã€ã«
ïŒminimum essentialïŒå¹å°äžã§å¹é€ããããã®
å¹å°çµæã¯ãäŸãã°ããçµç¹å¹é€ãäžäºæºä¹å©ä»
ç·šéãæåæžåºãæ¥æ¬ã1967幎ã«èšèŒãããŠã
ãããé 次å¹å°ã§åžéããè©ŠæïŒ0.1mlïŒãšïŒ¬âïŒ
现èã®å¹é€æžæ¿æ¶²ïŒ0.1mãïŒÃ105åïŒmlïŒãã
ã¬ãŒãã®åç©Žã®äžã§æ··åãããã®ãã¬ãŒããïŒïŒ
äºé žåççŽ ãå«æãã空æ°äžã§ã37âã§48æéå¹
é€ãããå¹é€çµäºåŸãã°ã«ã¿ã«ã¢ã«ããã20ÎŒ
ãå ã现èãåºå®ãããåºå®åŸããã¬ãŒããèžç
æ°Žã§æŽæµã也ç¥ããŠã0.05ïŒ ã¡ãã¬ã³ãã«ãŒ
ïŒ0.1mlïŒãå ããçãæ®ã€ã现èãæè²ãããã
ã¬ãŒããèžçæ°Žã§ååã«æŽæµãäœåãªã¡ãã¬ã³ã
ã«ãŒãé€å»ããŠä¹Ÿç¥ãããå¡©é žïŒ0.36NïŒãåç©Ž
ã«å ãæè²ãã现èããã¡ãã¬ã³ãã«ãŒãæœåº
ããåç©Žã®665nmã«ãããåžå 床ããããŒã»ã©ã
ã©ããªãŒç€Ÿè£œïŒç±³åœïŒã®ã¿ã€ã¿ãŒããã¯ã»ãã«ã
ã¹ãã€ã³ïŒTitertek MultiskanïŒã§æž¬å®ããã
ãã®åžå 床ã¯çãæ®ã€ã现èã®æ°ã«æ¯äŸãããïŒ
mlåœãïŒÃ105åã®ïŒ¬âïŒçŽ°èã®50ïŒ ã殺ãããš
ãã§ããæ¬çºæã®çç掻æ§ããªããããã®äžèšã®
éã¯ãåžéçãšåžå 床ãã°ã©ãã«ããããããã
ãšã«ãã€ãŠæ±ããããšãã§ããã æ¬çºæã®å»è¬çµæç©ã«ã也ç¬æ£è ã®æ²»çã«å¿ èŠ
ãªçšéã¯ãæ£è ã®å¹Žéœ¢ãçç¶ã«ãã€ãŠç°ãªããäž
èšã®ããã«ãæ¬çºæã®å»è¬çµæç©ã¯ãéåžžãæ°æ¥
ããæ°é±éã«ããããïŒæ¥50ãã108åäœã®çšé
ã§æäžããããšãã§ããããã®äžæ¥æäžéã¯ãäž
床ã«ããããã¯æ°åã«åããŠæ£è ã«æäžããããš
ãã§ãããæ¬çºæã®å»è¬çµæç©ã¯ãé£æ¥ãããã
ã¯ãééã眮ããŠæäžããããšãã§ããã代衚ç
ãªæäžæ¹æ³ã®äŸã次ã«ç€ºãã (a) ïŒé±éããïŒé±éã®é£æ¥æäžã (b) ïŒæ¥éæ¯æ¥æäžããåŸãïŒæ¥éããæ°é±éã®
äŒè¬ãã¯ããéæçæäžã (c) ïŒé±éã«ïŒåæäžã (d) ïŒæ¥éæ¯æ¥æäžããåŸãïŒã±æã®äŒè¬æéã
ã¯ããéæçæäžã ïŒçºæã®å¹æïŒ æ¬çºæã®å»è¬çµæç©ã¯ä¹Ÿç¬ã®æ²»çã«æ¥µããŠæå¹
ã§ãããå³ã¡ãé·ãé也ç¬ãç ©ã€ãŠããæ£è ãã
ä»ã®æ¹æ³ã«ããæ²»çã®åŸãäžå±€å¢æªããŠåçºãã
çäŸã«ãããæ¬å»è¬çµæç©ãé©å¿ããã°æ¥µããŠæ
å¹ã«æ²»çãããäºãã§ããã 次ã«å®æœäŸã«ãããã®çºæãæŽã«å ·äœçã«èª¬æ
ããã ïŒå®æœäŸïŒ åèäŸ ïŒ 155åã®ã¢ããé žããæãããTNFã¯ãç¹éæ
60â252496å·ã«èšèŒã®æ¹æ³ã«åŸã€ãŠçµæDNAæ
è¡ã«ãã€ãŠè£œé ããããã®ç¹èš±åºé¡å ¬éå ¬å ±ã®é
瀺å 容ã¯ãåç §ã«ãã€ãŠæ¬æ现æžã«èšèŒããã ãã®ããã«ããŠåŸãããããTNFã®ããè «ç
现èç³»ã«å¯Ÿãã现èå·å®³æŽ»æ§ã¯ã次ã®ããã«ããŠ
è©äŸ¡ããããšãã§ããã ããªãã¡ã1000åã®çŽ°èããåç©Žã«0.2mlã®ç°
ãªãæ¿åºŠã®ããTNFïŒïŒÃ104ããïŒÃ10-4å
äœïŒmlïŒãå«ã96ç©Žãã€ã¯ããã¬ãŒãäžã§å¹é€ã
ããïŒæ¥ä¹è³ïŒæ¥å¹é€ããåŸãTNFãå«ãŸãªã
ç©Žã§å¢æ®ããå¯Ÿç §çŽ°èã¯éå¯ç¶æ ã«ãªãã次ã«ã
çãæ®ã€ã现èã®æ°ãã¡ãã¬ã³ãã«ãŒã®å蟌ã¿ã«
ãã€ãŠæž¬å®ããã çµæã第ïŒè¡šã«ç€ºãã26现è系統ã®ããè «ç现
èã®ãã¡ãïŒç³»çµ±ïŒ15.3ïŒ ïŒã¯éææåæ§ã§ãã
ïŒïŒïŒïŒïŒIC50âŠ1.0åäœïŒmlïŒãïŒç³»çµ±ïŒ23.1ïŒ ïŒ
ã¯é«æåæ§ã§ããïŒïŒïŒïŒIC50âŠ10000åäœïŒ
mlïŒãïŒæ ªïŒ34ïŒ ïŒã¯æåæ§ãããïŒïŒïŒæå¶ç
â§20ïŒ ïŒãïŒæ ªïŒ20.9ïŒ ïŒã¯éæåæ§ã§ãã
ïŒâïŒæå¶çïŒ20ïŒ ïŒããã®ããã«ãããè «ç现è
系統ã®73ïŒ ããããTNFã«å¯ŸããŠæåæ§ã®ãã
ããšã瀺ããããäžæ¹ãæ£åžžäºåäœçŽ°èã«å¯Ÿãã
现èå·å®³æŽ»æ§ã¯èŠ³å¯ãããããŸããæé·åºæ¿äœçš
ãæ°ç³»çµ±ã®æ£åžžçŽ°èã§èŠ³å¯ãããã
ãããæŽã«è©³ããã¯ãããã®ä¹Ÿç¬ãæ²»çãããã
ã«æå¹æåãšããŠè «çå£æ»å åããªãã¡ãTNFã
ãå«æããå»è¬çµæç©ã«é¢ãããã®ã§ããã åŸæ¥ã®æè¡ ä¹Ÿç¬ã¯ãçœè²é±å±ã§è¢«èŠãããéå±æ§ã®çŽ æ
ãšããã°ãã°çš®ã ã®çšåºŠã®äžå¿«æã䌎ããšããã
ãšã«ãã€ãŠç¹åŸŽã¥ããããç¹æã®èšåºçç¶ã®ãã
å€ãããç¥ãããŠããæ ¢æ§ç®èçŸæ£ã§ãããæ¬çŸ
æ£ããäŒææ§ã§ã¯ãªãããšã¯æããã«ãããŠãã
ããæ¬çŸæ£ã®åå ãšæ©åºã¯ãŸã ååã«è§£æãããŠ
ããªããã¯ã«ãŒã¬ãŒããžãŒïŒãžãŒïŒïŒKrugerïŒG.
G.ïŒã也ç¬ïŒãã®ç å åŠãšçºç åŠã®æè¿ã®æŠå¿µã
ïŒâPsoriasisïŒCurrentConcepts of its Etiology
and PathogenesisâïŒã㶠ã€ã€ãŒ ãã㯠ãª
ã ããŒããããžãŒïŒThe Year Book of
DermatologyïŒïŒ1981幎ïŒããããœã³ãã¢ãŒã«ïŒ
ãšã«ïŒïŒDobsonïŒR.L.ïŒåã³ã·ã¢ãŒãºãããŒã»ãš
ããïŒïŒThiersïŒB.H.ïŒç·šéãã也ç¬ã¯ãç¬ç¹ã®
ç®èç å€åã³çºç¹ã圢æããããããã®è¢«å®³è ã«
瀟äŒç掻ãéã ãäžã§å¿ççé害ãäžããã西欧
è«žåœã§ã¯ãç·äººå£ã®çŽïŒïŒ ã也ç¬ã«çŸ æ£ããŠã
ãã 也ç¬ã¯å€å åæ§éºäŒçŸæ£ããããéºäŒççŽ å ã
èæ¯ã«ããããææãè¬ç©ãé£ç©ã颚åãã¹ãã¬
ã¹ãªã©ã®çš®ã ã®ä»ã®å åã®äœçšã«åºæ¿ããçºçã
ããšèããããŠããããããã®å åã®ãããã®ã
ãããã¯å šãŠããã®éºäŒççŽ å ã®åŒãéãšãªãåŸ
ãã也ç¬ããçµç¹é©åæ§æåïŒHLAïŒéºäŒåã®
å€æ§æ§ã«åºã¥ããŠå€åœ¢çŸè±¡ã瀺ãHLAãšå¯æ¥ã«
é¢é£ããŠããããšãç¥ãããŠããã®ã§ã也ç¬ãéº
äŒæ§çŸæ£ã§ããããšã¯æããã§ããã 也ç¬ç å€ã®çºçãšãã®å¯è§£ã¯ããã°ãã°äº€äºã«
æ°å¹Žéã«ãããçµéšãããã也ç¬ã«ã¯ïŒã€ã®ç¹åŸŽ
ççç¶ããããããªãã¡ãä»ã®è¡šåšæ§ç®èçŸæ£ãš
å ±éããççåå¿ãåã³è¡šç®ã®ç°åžžå¢æ®ååã§ã
ããå€ãã®ç 究è ãã¡ã¯ããã®ççåå¿ã®æ©åºã
å ç«åŠçåŽé¢ããããããŠè¡šç®ã®ç°åžžå¢æ®åŸåã®
æ©åºã现èççåŠçåŽé¢ãã解æããããšåªããŠ
ãããããã®æ©åºã¯ããŸã ååã«è§£æãããŠããª
ããããŠãŒãããŒãã€ãŒã»ãšããïŒBeutnerïŒE.
H.ïŒãã也ç¬ã«ãããèªå·±å ç«ãïŒâAutoimmunity
in PsoriasisâïŒãã·ãŒã¢ãŒã«ã·ãŒ ãã¬ã¹ïŒCRC
PressïŒãããŒã« ã©ãŒãã³ïŒBoca RatonïŒã
1982幎ãã 也ç¬ã¯ãç®èã®ççæ§è§åã䌎ãçŸæ£ã®ãã¡å ž
åçãªçŸæ£ã§ããã也ç¬ã«çœ¹æ£ããæ£è ã®æ°ã¯å¢
å ãã€ã€ããã也ç¬ã«å¯ŸããŠçš®ã ã®åé¡ããªãã
ãŠããããäžè¬ã«ã¯ãå°åžžæ§ä¹Ÿç¬ãè¿ç±æ§ä¹Ÿç¬ã
é¢ç¯çæ§ä¹Ÿç¬ã滎ç¶ä¹Ÿç¬ãªã©ã«åé¡ãããããã
ãã®ç åã®ãã¡å°åžžæ§ä¹Ÿç¬ãäž»èŠãªã¿ã€ãã§ãæ¬
çŸæ£ã®å šäŸã®80ïŒ ãã90ïŒ ãå ããã也ç¬ã«çœ¹æ£
ãããšãæ確ãªå¢çããã€ãçŽ æãããã¯çŽ è²äž
ç¹ãå€éšããã®èµ·çæ§åºæ¿ãåããããäœã®éš
åãäŸãã°ãé éšãèãèãèéšãªã©ã®éšåãã
现èããã³ãç¹æ®ããããææ¯éšåãªã©ã«çã
ãã 也ç¬ã«é¢ããŠããã®ç å€éšäœã«ããã圢æ åŠç
å€åã®ç¹åŸŽã«é¢ããäžè¬çãªç 究ããã®ç å€éšäœ
ã«ãããçååŠçãå ç«åŠçå€åã®ç¹åŸŽã«é¢ãã
ããæè¿ã®ç 究ãå«ããŠããŸããŸãªç 究ããªãã
ãŠããããããã«ããããããã也ç¬ã®æ ¹æ¬çå
å ã也ç¬ç å€ã®çºçæ©åºã¯ãããŸã 解æãããŠã
ãªãã也ç¬ã®å šãŠã®ã¿ã€ãã«ãããŠãæ§ã ã®çç¶
ãçŸè±¡ã芳å¯ãããŠãããããšãã°ã代è¬äº¢é²ã«
ãã现èã®é床ã®å ¥ã代ãã«ããè¡šç®çŽ°èã®è¥å
ãè§åç°åžžãè¡šç®ä¹³é å±€ã«ãããççåå¿ã®èã
ã亢é²ãçç®ã«ãããè¡ç®¡æ¡åŒµãšéèèè¡ããã³
è¡šç®çŽ°èå±€ãžã®å€æ žçœè¡çã®éèµ°ãšæµžæœ€ã芳å¯ã
ããã å»åž«ãã¡ã«ãã€ãŠåŸæ¥çšããããŠãã代衚çãª
也ç¬æ²»çæ³ã¯è¡šç®çŽ°èã®æ©èœäº¢é²æ§å¢æ®ãå¶åŸ¡ã
ãããšãççåå¿ãæå¶ããããšãå ç«èª¿ç¯ãä¿
é²ããããšãããã³çŽ°èããã³ã«ããææãé²ã
ããšã§ãããããšãã°ã以äžã®æ²»çæ¹æ³ãåŸæ¥çš
ããããŠããã (1) å¯è ç®è³ªãã«ã¢ã³ã®å€çšåã³å çš å¯è ç®è³ªãã«ã¢ã³ã®ãããªã¹ããã€ãã®å€çšã
ããã¯å±æç䜿çšã¯ã也ç¬ã®çç¶ã軜æžããå³æ
å¹æãç¹ã«çºç¹ã軜æžããå¹æãæãããããã®
æ²»çã®ããã«ã¯é·æéã«ãããå¯è ç®è³ªãã«ã¢ã³
ã®æäžãå¿ èŠã§ãããé·ææäžã¯ã¿ããã€ã©ãã·
ãŒçŸè±¡ïŒTachyphylaxisïŒãå³ã¡æ £ãã®çŸè±¡ãåŒ
ãèµ·ããããã®ãããæãŸããæ²»çå¹æãåŸãã
ãã«ã¯çšéã®å¢å ããããã¯ãã匷ãè¬ç©ã®äœ¿çš
ãå¿ èŠãšãªããææãå¯è ç®è³ªãã«ã¢ã³ã«ãã€ãŠ
æ²»çããéšäœã«æ°ããç å€ã®çºçã芳å¯ããããš
ããããå¯è ç®è³ªãã«ã¢ã³ããã³ãŒãã€ã³ã°å€ã
è»èãå¡åžå€ã®åœ¢æ ã§ç®èã«æäžããå Žåãå¯è
ç®è³ªãã«ã¢ã³ã®äœçšã¯ãç å€éšäœã ãã§ã¯ãªãåš
å²ã®æ£åžžãªç®èã«ãåã³ããã®æ£åžžéšäœã«ãããŠ
çç®ã®èçž®ãšèŒçœåããããã¯ã¹ããã€ã座ç¡ã
åŒãèµ·ããããã ããã«ãå¯è ç®è³ªãã«ã¢ã³ã®å¯äœçšãé¿ããã
ãããã®ãã«ã¢ã³ã®æäžãäžæ¢ãšãããšãåè·³çŸ
象ãšããŠç®èçããã°ãã°çããããç å€ã¯æ¡å€§
ãæªåããåŸåã«ããããã®ãããªåè·³çŸè±¡ãšã
ãŠçããç®èçã¯ãç¹ã«ãå æè¬ã®æäžãäžæ¢ã
ãå Žåã«èµ·ããããããåŸã€ãŠãç å€ãç®èã®æ¯
èŒçåºãéšäœã«ã¿ãããå Žåããã®æ¹æ³ã ãã§å®
å šã«æ²»çããããšã¯ã§ãããä»ã®æ²»çæ³ãšã®äœµçš
ãå¿ èŠã§ããã (2) å ååŠçæ³ ãã®æ¹æ³ã¯ããœã©ã¬ã³ïŒpsoralenïŒãå€çšå€ã
ããã¯å æè¬ã®åœ¢æ ã§æäžãã次ãã§é·æ³¢é·ã®çŽ«
å€ç·ãæ£éšã«ç §å°ããããšãããªããããããã
ã®æ¹æ³ã§æ²»çã§ããªãã¿ã€ãã®ä¹Ÿç¬ãããããã
ã«æ¥å çæ³ãšåæ§ã«ãã®çæ³ãé·æéè¡ãªããšã
ç®èã«èåã«äŒŒãçŸè±¡ãèµ·ããã ãã§ãªããç¹åŸŽ
çãªè²çŽ æã®åœ¢æãèµ·ãããããã (3) å çæ³ïŒUVç §å°ïŒ æ¥å çæ³ã®å Žåãšåæ§ã«ã玫å€ç·ç §å°ãé·æé
å®æœãããšãç®èã®èåä¿é²ãåŒãèµ·ããããã
ãã§ãªããçºçã®èªçºãèµ·ããåŸãã (4) ã³ãŒã«ã¿ãŒã«ã®å€çšçæ³ ã³ãŒã«ã¿ãŒã«ã¯è¡šç®çŽ°èã®æé·ãæå¶ããã®
ã§ãç å€ãçæéã«æ¶å€±ããæ¯èŒçé·ãå¯è§£æé
ãéæããããããããæãšããŠãåºæ¿æ§ç®èç
ãæ¯ãçïŒã¿ãŒã«åº§ç¡ïŒãåŒããããããããšã
ããã (5) ã¡ããã¬ãã»ãŒãïŒmethotrexateïŒã®æäž ã¡ããã¬ãã»ãŒãã¯ãèé žã«å¯Ÿããæ®æç©è³ª
ã§ã现èã®æé·ãæå¶ããäœçšããããã¡ããã¬
ãã»ãŒãã®äœ¿çšã¯ãè¿ç±æ§ä¹Ÿç¬ã®æ²»çã«å¹æãã
ãããé·æéæäžãããšãèæ©èœé害ã骚é«æå¶
ãªã©ã®å¯äœçšãèµ·ããã (6) ã¬ããã€ãïŒretinoidïŒã®æäž ã¬ããã€ãã¯å ç«èª¿ç¯äœçšãæãããšèããã
ãŠãããããªãã¡ãã¬ããã€ãã¯è¡šç®çŽ°èã®ç°åžž
è§åãšçœè¡çéèµ°ã®æ©èœäº¢é²ãæå¶ããããšãã¬
ãããŒãïŒetretinateïŒã®ãããªã¬ããã€ãã®å
ææäžã¯è¿ç±æ§ä¹Ÿç¬ãšä¹Ÿç¬æ§çŽ ç®çã®æ²»çã«ç¹ã«
å¹æçã§ãããããããªããããã°ãã°ç®èãå¯
èŠç²èã®åããèããªããšããå¯äœçšãããããŸ
ããè¡æž ãªãã¿ã³ãã¯æ¿åºŠã®ç°åžžããã°ãã°èŠ³å¯
ããããããã«ãã¬ããã€ãã«ã¯å¬å¥åœ¢æ§äœçšã
ãããäœå ã«èç©ãããããåãé·æéäœå ã«æ®
çããåŸåã«ããããã®ãããåŠåš å¯èœãªå¥³æ§ã«
ã¬ããã€ãã䜿çšããããšã¯é¿ããã¹ãã§ããã
åŸã€ãŠãéåžžãã¬ããã€ãã¯ãåŠåš å¯èœãªå¹Žéœ¢ã
éãã女æ§æ£è ããããã¯é£æ²»æ§ä¹Ÿç¬ã«çœ¹æ£ããŠ
ããæ£è ã®ã¿ã察象ã«ããŠçšããããã äžèšã®ããã«ãå¯è ç®è³ªãã«ã¢ã³ã¯ãããçšåºŠ
也ç¬çç¶ã軜æžããå³æå¹æã瀺ãããã¿ããã€
ã©ãã·ãŒçŸè±¡ãèµ·ããããããããã®ãã«ã¢ã³ã
é£ç¶æäžããããšãå°é£ã§ãããããã«å¥œãŸãã
ãªãããšã«çšéãå¢å ããªããã°ãªããªããªãã
ãã®ãããªå ŽåãäŒè¬ãããããããã¯å¯äœçšã
é¿ãããããã®ãã«ã¢ã³ã®æäžãäžæ¢ãããšãã
ã°ãã°åè·³çŸè±¡ãšããŠç®èçããããçç¶ããã
ã«æªåãããåŸã€ãŠãå¯è ç®è³ªãã«ã¢ã³åç¬ã§å¹
æçã«ä¹Ÿç¬ãæ²»çããããšã¯é£ãããå ååŠçæ³
ããã³ãŒã«ã¿ãŒã«ãã¢ã³ã¹ã©ãªã³ïŒanthralinïŒã
ã¬ããã€ããªã©ã®è¡šç®çŽ°èå¢æ®æå¶å€ã䜿çšãã
çæ³ãå¯è ç®è³ªãã«ã¢ã³ãšäœµçšãããšãããçšåºŠ
ã®æ²»çå¹æã¯éæã§ãããããããªããã也ç¬ã
å®å šã«æ²»çããããšã¯ã§ããªãããã¬ããŒã¯ããš
ããïŒãšããïŒïŒãžãšãŒã¢ãŒã«ïŒRoenigkïŒH.
H.ïŒJr.ïŒåã³ãã€ã³ãããããšããïŒã¢ã€ïŒ
ïŒMainnbachïŒH.I.ïŒãããœã©ã€ã¢ã·ã¹
ïŒPsoriasisïŒãããŒã»ã«ããã«ãŒç€ŸïŒMarcel
Dekker Inc.ïŒãããŠãŒãšãŒã¯ã1985幎ãã çºæã解決ããããšããèª²é¡ åŸã€ãŠãæ¬çºæã®ç®çã¯ã也ç¬æ²»çã«æå¹ãªæ°
èŠå»è¬çµæç©ãæäŸããããšã«ããã æ¬çºæã®å¥ã®ç®çã¯ãçŸåšç¥ãããŠããçµæç©
ã®ãã€æ¬ ç¹ãå®è³ªäžãªã也ç¬æ²»çã«æå¹ãªå»è¬çµ
æç©ãæäŸããããšã«ããã 課é¡ã解決ããããã®æ段 æ¬çºæã®äžèšã®ç®çã¯ãæ¬çºæè ãã®çºèŠã
ããå ¬ç¥ã®æ²»çè¬ãæ²»çæ¹æ³ã«äžå¯é¿çã«äŒŽãäž
èšã®æ¬ ç¹ãæããªãæ°ããã¿ã€ãã®å»è¬çµæç©å
ã³ãã®å»è¬çµæç©ã也ç¬ã®æ²»çã«çšããæ¹æ³ã«ã
ã€ãŠéæãããããã®çºèŠãšã¯è©³ããã¯ãè «çå£
æ»å åãããªãã¡TNFããå ¬ç¥ã®åŠäœãªãæ²»ç
è¬ãæ²»çæ¹æ³ã§ãæ²»çã§ããªãã€ã也ç¬æ£è ã«æ
äžãããšãçç¶ãå šèº«ããæ¶å€±ãããšããããšã§
ããã æ¬çºæã«ããã°ã也ç¬æ²»çã«æå¹ãªéã®TNF
ãšå°ãªããšãäžçš®ã®å»è¬æäžå¯èœãªæ äœãåžéå€
ãããã¯è³Šåœ¢å€ãå«æãã也ç¬æ²»ççšã®æ°èŠå»è¬
çµæç©ãæäŸãããããã也ç¬æ£è ã®æ²»çã«çšã
ãããæ¬çºæã®å»è¬çµæç©ã«ãããŠã¯ãè «çå£æ»
å åã¯ãããç±æ¥ã®çŽ°èããããããã¯çµæã
DNAæè¡ã«ãã€ãŠè£œé ããããã®ã§ããããšã
奜ãŸããããã®ãããªçµæç©ã«ã¯ãäŸãã°ãéè
å 泚å°çšãçèå 泚å°çšãç®äžæ³šå°çšãç®å 泚å°
çšãçµå£æäžçšãçŽè žå æäžçšãå€éšæœçšçšãå±
ææœçšçšãç¹çŒçšãªã©ã«é©åããæäžåœ¢æ ãäžã
ãããšãã§ãããããã«ãæ¬çºæã®å»è¬çµæç©ã¯
ããªããããçµæç©ã«é©åããæäžåœ¢æ ãäžãã
ããšãã§ããã è «çå£æ»å åãããªãã¡TNFã¯ãçåèœåã®
ãããã€ã¯ããã¯ããªãŠã ããŒãã¢ã€ã¹
ïŒMicrobacterium boviceïŒã®ããã«ã¹ã«ã«ã¡
ãããŒã°ãšãªã³ïŒBacillus CalmetteâGuerinïŒ
æ ªïŒBCGïŒãåæäžåŸã现èã®ãšã³ãããã·ã³
ãéèå æäžããããŠã¹ã®è¡æž äžããåããŠçºèŠ
ããããããã·ãŒãã€ã³ã°ã¹ã»ãªãã»ãã·ãšã
ã«ã»ã¢ã«ãããŒã»ãªãã»ãµã€ãšã³ã¹ã»ãŠã»ãšã¹ã»
ãšãŒïŒProc.Nat.Acad.Sci.U.S.A.ïŒ72巻第ïŒå·ã
3666â70é ïŒ1975幎ïŒããTNFãå«æããããŠã¹
è¡æž ã¯ãin vitroè©Šéšã§å€æ°ã®ããŠã¹åã³ãã
圢質転æ现èç³»ã«å¯ŸããŠçŽ°èå·å®³æŽ»æ§äœçšããã
ã¯é现è掻æ§ã瀺ããããããã®äœçšã¯æ£åžžçŽ°è
ã«å¯ŸããŠã¯éåžžã«åŒ±ããTNFãå«æããããŠã¹
è¡æž ã¯ãããŠã¹ã«ç§»æ€å¯èœãªè «çã®å£æ»ãçãã
ããããTNFã¯ã©ãããã«ãµã®åã³ã¢ã«ã¢ãã
ã®è¡æž äžã«ãç£çãããããã«ãTNFã¯åºä¹³é¡
ç±æ¥ã®åæ žé£çŽ°èãç¹ç¶èœçŽ°èã现èãªã©ã«ã
ã€ãŠãããæ¡ä»¶äžã«ãããŠç£çããåŸããã®ã§ã
ããããã«é¢ããŠã¯ããã€ã ãžãšã€ïŒãªãŒã«ã
ïŒLloyd J.OldïŒã«ãã€ãŠãµã€ãšã³ãã€ãã€ãã¯
ã¢ã¡ãªã«ã³ïŒScientific AmericanïŒ258巻第ïŒ
å·59â75é ïŒ1988幎ïŒæïŒã®ç·èª¬ã«åŒçšãããæ
ç®äžã«å€ãã®å ±åããããæ¬çºæã«ãããŠã¯ãåº
ä¹³é¡ç±æ¥ã®è¡æž ãããã¯åºä¹³é¡ç±æ¥ã®çŽ°èããåŸ
ãããäžèšTNFã掻æ§æåãšããŠçšããããšã
ã§ãããæ¬çºæã®å¥œãŸããæ æ§ã«ãããŠã¯ãå ç«
é©åæ§çã®ç¹ããããŠãå°ãªããšãããTNFã
å«æããå»è¬çµæç©ãçšããããšã奜ãŸããã åèšããTNFã¯ãçµæãDNAæè¡ã«ãã€ãŠè£œ
é ããããšãã§ããããããç±æ¥ã®çŽ°èãå¹é€ã
ãããšã«ãã€ãŠã補é ããããšãã§ããã çµæãDNAæè¡ã«ããããTNFã補é ããã«
ã€ããŠã¯ãããšãã°ãã·ã©ã€ ãã€ãŒïŒïŒShirai
T.ïŒããããŒãã€ãŒïŒNatureïŒã313å·»803â806
é ïŒ1985幎ïŒãç¹éæ60â252496å·ïŒæ¬§å·ç¹èš±åº
é¡å ¬éç¬¬ïŒ 158 286å·ã«å¯Ÿå¿ïŒã«èšèŒãããŠã
ãæ¹æ³ãæ¡çšã§ããããããã®æç®ã«èšèŒããã
æ¹æ³ã«ããã°ãäŸãã°ãå€§è žèã®å¹é€ã«ãã€ãŠå
質ãªããTNFãå¹ççã«åŸãããšãã§ããã äŸãã°ã次ã®ããã«ããŠåèšããTNFã補é
ããããšãã§ãããããªãã¡ã50ÎŒïœïŒmlã®ã¢ã³
ãã·ãªã³ãå«æããã«ãªã¢å¹å°ïŒLuria brothïŒ
äžã§å¹é€ããå€§è žèK12ïŒD1212ïŒïŒpHNtac4ã®
èäœãé å¿åé¢ã«ãã€ãŠéãã10åãã³ãã³âãŽ
ãŒãªã³ãã¬ã¹ïŒMantonâGaulin pressïŒããŽãŒ
ãªã³ç€ŸïŒGaulin CO.ïŒè£œãç±³åœããéãæ¿Ÿéã
ããäžæž ãšããŠåŸããã现è溶è液ã¯ãã¿ã³ãã¯
質ïŒmgåœã32000åäœã®æ¯æŽ»æ§ãæã€ããã®çŽ°è
溶è液ã20mMããªã¹âå¡©é žç·©è¡æ¶²ïŒPH8.0ïŒã§
平衡åããDEAEã»ãã¢ããã¯ã¹CLâ6Bã«ã©ã
ïŒãã¢ã«ãã·ã¢ç€Ÿè£œãã¹ãŠãšãŒãã³ïŒã«ããã
100mMå¡©åãããªãŠã ãå«ã20mMããªã¹âå¡©
é žç·©è¡æ¶²ãçšããŠPH8.0ã§æº¶é¢ãããâ现èå·
害掻æ§ãæã€ç»åãããŒã«ããããã«éçååé
ã®6000ã®ããªã¹ã«ãã³ããªããŒãã¢ã€ããŒ
ïŒpolysulfone hollow fiberïŒæåææ ªåŒäŒç€Ÿè£œïŒ
ãçšããŠæ¿çž®ããããã®æ¿çž®æ¶²ã60âã§30åéé
ãã«æªæããªããå ç±ãã0.2ÎŒmèïŒãããŒã©ã
ã©ããªãŒç€Ÿè£œãç±³åœïŒãçšããŠæ¿Ÿéããããã®ãµ
ã³ãã«ã150mMå¡©åãããªãŠã ãå«ã20mMã
ãªã¹âå¡©é žç·©è¡æ¶²ïŒPH8.0ïŒã§å¹³è¡¡åããå¥ã®
DEAEâã»ãã¢ããŒã¹GLâ6Bã«ã©ã ïŒ2.6Ã11
cmïŒã«ããã掻æ§ç©è³ªã150mMå¡©åãããªãŠã
ãå«ã20mMããªã¹âå¡©é žç·©è¡æ¶²ïŒPH8.0ïŒã§æº¶
é¢ãã掻æ§ç»åãããŒã«ããããã®æŽ»æ§ç»åã
150mMå¡©åãããªãŠãã ãå«ã5mMãªã³é žãã
ãªãŠã ïŒPH7.4ïŒäžã§ã»ãã¢ã¯ãªã«ïŒ³â200ã«ã©ã
ïŒãã¢ã«ãã·ã¢ç€Ÿè£œãã¹ãŠãšãŒãã³ïŒã«ãããã
掻æ§ç»åã¯ååé45000ã®ç»åã«çžåœããTNF掻
æ§ã®ååçã¯41ïŒ ã§ããã ãã®ããã«ããŠåŸãããããTNFã¯ã¿ã³ãã¯
質ïŒmgåœãçŽ1.4Ã106åäœã®æ¯æŽ»æ§ãæãã
BALBïŒïœããŠã¹ã®è ¹è å ã«ç§»æ€ããã¡ã¹ïŒ¡è
è «ã®åºè¡æ§å£æ»ãèªçºããããã®TNAã¯ãŸã å®
å šã«ã¯ç²Ÿè£œãããŠããªããåŸã€ãŠãå¿ èŠã«å¿ããŠ
ããé«çŽåºŠã®ããTNFãåŸãããã«äžèšã®æè¡
ãåç¬ã§ããããã¯çµåããŠããã«ç²Ÿè£œããããš
ãã§ããããªããããTNF掻æ§ã¯ãâïŒçŽ°è
ãã¢ã¡ãªã«ã³ ã¿ã€ã ã«ã«ãã€ãŒã³ã¬ã¯ã·ãšã³ã
ã·ãŒã·ãŒãšã«1.2ïŒAmerican Type Culture
CollectionïŒCCL1.2ïŒããçšãããŠã€ãªã¢ã ãœã³
çïŒWilliamson etal.ïŒã®æ¹æ³ã®å€æ³ã«ããããŠ
ã¹ïŒ¬â现èã«å¯Ÿãã殺现è掻æ§ã«ãã€ãŠç¥ãããš
ãã§ãããã¢ã¹ ããŒïŒïŒMoss B.ïŒãããã·ãŒã
ã€ã³ã°ã¹ã»ãªãã»ãã·ãšãã«ã»ã¢ã«ãããŒã»ãª
ãã»ãµã€ãšã³ã¹ïŒãŠãŒïŒãšã¹ïŒãšãŒïŒProc.Nat.
Acad.Sci.U.S.A.ïŒ80å·»5397â5401é ïŒ1983幎ïŒãã
çå现èæ°ã¯ã©ãïŒRuffïŒãšã®ããªãŒã
ïŒGiffordïŒã®å 床枬å®æ³ã«ãã€ãŠæž¬å®ããããžã€
ãŒãã« ãªã ã€ã ãããžãŒïŒJ.Immun.ïŒ125å·»
1671â1677é ã1980幎ãã åèšããTNFã¯ãäžè¿°ããæ¹æ³ä»¥å€ã«ããã€
ã¢ã³ ããã«ïŒDiane PennicaïŒããããŒãã€ãŒ
ïŒNatureïŒã312å·»ã20â27é ïŒ1984幎12æïŒã«èš
èŒããæ¹æ³ãã欧å·ç¹èš±åºé¡å ¬é第168214å·åã³
第155549å·ãªã©ã«èšèŒãããŠããä»ã®å ¬ç¥ã®æ¹æ³
ã«ãã€ãŠã補é ããããšãã§ããã ããTNFãæ§æããã¢ããé žã®æ°ã¯ãTNFã
åŸããããã«çšãã補é æ¹æ³ã«ãã€ãŠç°ãªããã
ãšãã°ãç¹éæ60â252496å·ã«èšèŒãããŠããçµ
æãDNAæè¡ã«ãã€ãŠè£œé ãããããTNFã¯
155åã®ã¢ããé žããæããäžæ¹ãäžèšã®ããã«
ïŒPennicaïŒçã®æ¹æ³ã«ãã€ãŠè£œé ããããã
TNFã¯157åã®ã¢ããé žããæããäžèšã®155å
ã®ã¢ããé žãšããã®ïŒ®æ«ç«¯ã«çµåããïŒåã®ã¢ã
ãé žãããªãé åãæããã çµæãDNAæè¡ã«ãã€ãŠè£œé ãããTNFã¯ã
äžèšã®ã¢ããé žé åã®ïŒ®æ«ç«¯ã«ã¡ããªãã³æ®åºã
çµåããŠããããªãããããšãäžèšã®ã¢ããé žé
åã®ïŒ®æ«ç«¯ã«ããTNFã®ãžã°ãã«ããããã®äž
éšåãããã¯å šéšãçµåããŠããäžéäœãå å«ã
ããèªç¶ã®å€ç°ããããã¯äººçºçå€ç°ã«ãã€ãŠã
ãã®ããªããããã®æŽ»æ§ã«ææãªå€åãçããã
ãšãªãããªãããããã³ãŒãããDNAã®æ§é ã®
äžéšãå€ããããšã¯å¯èœã§ããã æ¬çºæã§çšããããšã®ã§ããããTNFã¯ãäž
èšã®ã¢ããé žé åãæããããªããããã®çžåå€
ç°äœïŒhomologous variantïŒã«çžåœããæ§é ã
æããããªãããããå å«ãããçžåå€ç°äœã®äŸ
ãšããŠãç±³åœç¹èš±ç¬¬4677063å·ãšç¬¬4677064å·ã«èš
èŒãããŠãããããããæãããããã®é瀺å 容
ã¯ãåç §ã«ãã€ãŠæ¬æ现æžã«èšèŒããããããã
ã¹ãŠã®çç掻æ§ãããããã以äžãããTNFã
ãšç§°ããã 倩ç¶ã®ããTNFã¯ãçååŠç修食ãããã¯å
åŠç修食ãåãæãããŸããïŒéäœãïŒéäœã®ã
ããªäŒåäœã®åœ¢ã«ãªãæããããããªããããã
ãã®TNFããªããããããŸããæ¬çºæã®å»è¬çµ
æç©ã®æŽ»æ§æåãšããŠäœ¿çšã§ããã æ¬çºæã®å»è¬çµæç©ã¯ãåºæ¬çã«ã¯äžè¿°ããè «
çå£æ»æŽ»æ§ãæããTNFãæå¹æåãšãããã®
ã§ããããä»ã®è «çå£æ»æŽ»æ§ãæããç©è³ªãäŸã
ã°ãªã³ãããã·ã³ãçµæç©äžã«å«æããããŠãã
ãã æ¬çºæã®å»è¬çµæç©ã¯ãäŸãã°ãéèå 泚å°ã
çèå 泚å°ãç®äžæ³šå°ãç®å 泚å°ãçµå£æäžãçŽ
è žå æäžãå€çšããããã¯ç¹çŒçšçã«é©ããçš®ã
ã®è£œå€ã®åœ¢æ ã«èª¿è£œããããšãã§ãããæ¬è£œå€ã¯
ããªããããçµæç©ã®æäžã«é©åãã圢æ ã«èª¿è£œ
ããã®ãæçšã§ããã æ¬çºæã®å»è¬çµæç©ã調補ããã«éããæ¬çºæ
ã®å»è¬çµæç©ã«çš®ã ã®æ·»å ç©ãäŸãã°ãå°ãªããš
ãïŒçš®ã®æ äœãåžéå€ã賊圢å€ãæµåå€ãçµå
å€ãå®å®åå€ãå¢ç²å€ãPH調æŽå€çãé©å®å ãã
ããšãã§ããã 奜é©ãªæ äœãåžéå€åã³è³Šåœ¢å€ãšããŠã¯ããžã€
ã¬ã€ã¢æŸ±ç²ãããŠã¢ãã³ã·æŸ±ç²ãããã¹ããªã³ã
å°éºŠæŸ±ç²ãããããã·ãããã«æŸ±ç²çã®æŸ±ç²é¡ã
ä¹³ç³ããããŠç³ãã·ãšç³ããã³ããŒã«ããœã«ãã
ãŒã«çã®ç³é¡ãã¡ãã«ã»ã«ããŒã¹ãã«ã«ããã·ã«
ã¡ãã«ã»ã«ããŒã¹ããã³ããããã·ãããã«ã»ã«
ããŒã¹çã®ã»ã«ããŒã¹é¡ãå¡©åãããªãŠã ãããŠ
é žãç¡«é žã«ã«ã·ãŠã ããªã³é žã«ã«ã·ãŠã ãæ²éç
é žã«ã«ã·ãŠã çã®ç¡æ©ç©ãæããããã 奜é©ãªæµååå€ãšããŠã¯ãé žåãã°ãã·ãŠã ã
åæã±ã€é žã¢ã«ãããŠã ãã¡ã¿ã±ã€é žãã¢ã«ãã³
é žãã°ãã·ãŠã ãå«æ°Žã±ã€é žãç¡æ°Žã±ã€é žãã¿ã«
ã¯ãã¹ãã¢ãªã³é žãã°ãã·ãŠã ãã«ãªãªã³çãæ
ããããã 奜é©ãªçµåå€ãšããŠã¯ãããªãšãã¬ã³ã°ãªã³ãŒ
ã«ãããªããã«ãããªãã³ãããªããã«ã¢ã«ã³ãŒ
ã«ãã¢ã©ãã¢ãŽã ããã©ã¬ã³ããã¢ã«ã®ã³é žãã
ãªãŠã ããŒã©ãã³ãã°ã«ãã³çãæããããã 奜é©ãªå®å®åå€ãšããŠã¯ãã¢ã«ããã³ãããã¿
ãã³ããŒã©ãã³ãã°ã«ããªã³ãªã©ã®ã¿ã³ãã¯è³ªã
ã¢ããé žåã³ãã®å¡©é¡ãªã©ãæããããã 奜é©ãªå¢ç²å€ãšããŠã¯ãã·ãšç³ãã°ãªã»ãªã³ã
ã¡ãã«ã»ã«ããŒã¹ãã«ã«ããã·ã¡ãã«ã»ã«ããŒã¹
çãæããããã 奜é©ãªPH調æŽå€ãšããŠã¯ãå¡©é žãæ°Žé žåãããª
ãŠã ããªã³é žå¡©ãã¯ãšã³é žå¡©ãçé žå¡©çãæãã
ããã æ¬çºæã®å»è¬çµæç©ãé å€ã®åœ¢æ ã®å Žåã¯ãäž
èšã®å®å®å€ã«å ããä¹³ç³ãã©ã¯ããŒã¹çã®æ äœã
æ·»å ããããšãã§ããã æ¬çºæã®å»è¬çµæç©ã¯å¡åžå€ãè»èãã¯ãªãŒ
ã ããããã¯å±ææäžã«é©ããä»ã®è£œå€åœ¢æ ãäŸ
ãã°ãšã¢ããŸã«ã湿åžå€ãããå€ãªã©ã®ãããã®
圢æ ã«èª¿è£œããŠçšããŠç®èãžã®æå¹æåã®æµžéã
ä¿é²ããããšãã§ããããã®ãããªå Žåãçé¢æŽ»
æ§å€ãç²çå€ãæ²¹æ§åºå€çãæ·»å ããããšãã§ã
ãã 奜é©ãªçé¢æŽ»æ§å€ãšããŠã¯ãã©ãŠãªã«ç¡«é žãã
ãªãŠã ãããŠã€ãŒã³ïŒTweenïŒç³»çé¢æŽ»æ§å€
ïŒããªãªãã·ãšãã¬ã³ã°ãªã³ãŒã«ãœã«ãã¿ã³ã¢ã«
ãã«ãšã¹ãã«é¡ïŒãã¹ãã³ïŒSpanïŒç³»çé¢æŽ»æ§å€
ïŒã¢ã·ã«ãœã«ãã¿ã³ïŒçãæããããã 奜é©ãªç²çå€ãšããŠã倩ç¶ãŽã ãããã«ãŽã ã
ããªã€ãœããã¬ã³ãããªã¢ã«ãã«ã¢ã¯ãªã¬ãŒãã
ããªãã«ãã³æš¹èçãæããããã 奜é©ãªæ²¹æ§åºå€ãšããŠã¯ãé«çŽèèªæã¢ã«ã³ãŒ
ã«ãé«çŽèèªé žãšã¹ãã«ãããŠãããªã°ãªã»ã©ã€
ããã¢ãã°ãªã»ã©ã€ããæµåãã©ãã€ã³ãã¢ã€ãœ
ããŒïŒã³ãã©ãã€ããŒãïŒãã¯ã»ãªã³ç³æ²¹ãŒãªãŒã
ïŒãããã©ã¿ã ïŒãã·ãªã³ã³æ²¹ããã©ããªã³ãæ¹è¯
æ€ç©æ²¹ãããã·æ²¹ã®ãããªå€©ç¶æ²¹çãæããã
ãã æ¬çºæã®å»è¬çµæç©ã¯ãæ人ã«å¯ŸããTNFã®
äžæ¥æäžéãšããŠãäžè¬ã«çŽ50ãã100000000å
äœã®çšéã§ã奜ãŸããã¯ãå±ææäžã®å Žåã«ã¯ã
çŽ50ãã500000åäœã®çšéã§ãéèå æäžãçè
å æäžã®ãããªäžè¬çãªæäžã®å ŽåãçŽ1000ãã
10000000åäœã®çšéã§ããããŠçµå£æäžã®å Žåã«
ã¯ãçŽ10000ãã100000000åäœã®çšéã§ä¹Ÿç¬æ£è
ã«æäžããããšãã§ãããäžæ¥ã®æäžéã¯ãæ£è
ã®çç¶ã«å¿ããŠå¢æžã§ããã äžèšã«ãããŠçšãããïŒåäœïŒïŒµïŒãã¯ïŒmlåœ
ãïŒÃ105åã®ïŒ¬âïŒçŽ°èãã¢ã¡ãªã«ã³ ã¿ã€ã
ã«ã«ãã€ãŒ ã³ã¬ã¯ã·ãšã³ ã·ãŒã·ãŒãšã«1.2
ïŒAmerican Type Culture Collection CCL1.2ïŒã
ã®50ïŒ ã殺ãTNFã®éãæå³ããããã®éã¯æ¬¡
ã®ããã«ããŠæž¬å®ã§ãããããªãã¡ãå¹é€å®¹åšãš
ããŠã96ç©Žã®çµç¹å¹é€çšãã€ã¯ããã¬ãŒãïŒãã
ãŒã©ãã©ããªãŒç€Ÿè£œãç±³åœïŒãçšããâïŒçŽ°è
ã1vïŒïœïŒ ã®ãŠã·èå è¡æž ãå«ãã€ãŒã°ã«
ïŒEagleïŒã®ãããã ã»ãšãã»ã³ã·ã€ã«
ïŒminimum essentialïŒå¹å°äžã§å¹é€ããããã®
å¹å°çµæã¯ãäŸãã°ããçµç¹å¹é€ãäžäºæºä¹å©ä»
ç·šéãæåæžåºãæ¥æ¬ã1967幎ã«èšèŒãããŠã
ãããé 次å¹å°ã§åžéããè©ŠæïŒ0.1mlïŒãšïŒ¬âïŒ
现èã®å¹é€æžæ¿æ¶²ïŒ0.1mãïŒÃ105åïŒmlïŒãã
ã¬ãŒãã®åç©Žã®äžã§æ··åãããã®ãã¬ãŒããïŒïŒ
äºé žåççŽ ãå«æãã空æ°äžã§ã37âã§48æéå¹
é€ãããå¹é€çµäºåŸãã°ã«ã¿ã«ã¢ã«ããã20ÎŒ
ãå ã现èãåºå®ãããåºå®åŸããã¬ãŒããèžç
æ°Žã§æŽæµã也ç¥ããŠã0.05ïŒ ã¡ãã¬ã³ãã«ãŒ
ïŒ0.1mlïŒãå ããçãæ®ã€ã现èãæè²ãããã
ã¬ãŒããèžçæ°Žã§ååã«æŽæµãäœåãªã¡ãã¬ã³ã
ã«ãŒãé€å»ããŠä¹Ÿç¥ãããå¡©é žïŒ0.36NïŒãåç©Ž
ã«å ãæè²ãã现èããã¡ãã¬ã³ãã«ãŒãæœåº
ããåç©Žã®665nmã«ãããåžå 床ããããŒã»ã©ã
ã©ããªãŒç€Ÿè£œïŒç±³åœïŒã®ã¿ã€ã¿ãŒããã¯ã»ãã«ã
ã¹ãã€ã³ïŒTitertek MultiskanïŒã§æž¬å®ããã
ãã®åžå 床ã¯çãæ®ã€ã现èã®æ°ã«æ¯äŸãããïŒ
mlåœãïŒÃ105åã®ïŒ¬âïŒçŽ°èã®50ïŒ ã殺ãããš
ãã§ããæ¬çºæã®çç掻æ§ããªããããã®äžèšã®
éã¯ãåžéçãšåžå 床ãã°ã©ãã«ããããããã
ãšã«ãã€ãŠæ±ããããšãã§ããã æ¬çºæã®å»è¬çµæç©ã«ã也ç¬æ£è ã®æ²»çã«å¿ èŠ
ãªçšéã¯ãæ£è ã®å¹Žéœ¢ãçç¶ã«ãã€ãŠç°ãªããäž
èšã®ããã«ãæ¬çºæã®å»è¬çµæç©ã¯ãéåžžãæ°æ¥
ããæ°é±éã«ããããïŒæ¥50ãã108åäœã®çšé
ã§æäžããããšãã§ããããã®äžæ¥æäžéã¯ãäž
床ã«ããããã¯æ°åã«åããŠæ£è ã«æäžããããš
ãã§ãããæ¬çºæã®å»è¬çµæç©ã¯ãé£æ¥ãããã
ã¯ãééã眮ããŠæäžããããšãã§ããã代衚ç
ãªæäžæ¹æ³ã®äŸã次ã«ç€ºãã (a) ïŒé±éããïŒé±éã®é£æ¥æäžã (b) ïŒæ¥éæ¯æ¥æäžããåŸãïŒæ¥éããæ°é±éã®
äŒè¬ãã¯ããéæçæäžã (c) ïŒé±éã«ïŒåæäžã (d) ïŒæ¥éæ¯æ¥æäžããåŸãïŒã±æã®äŒè¬æéã
ã¯ããéæçæäžã ïŒçºæã®å¹æïŒ æ¬çºæã®å»è¬çµæç©ã¯ä¹Ÿç¬ã®æ²»çã«æ¥µããŠæå¹
ã§ãããå³ã¡ãé·ãé也ç¬ãç ©ã€ãŠããæ£è ãã
ä»ã®æ¹æ³ã«ããæ²»çã®åŸãäžå±€å¢æªããŠåçºãã
çäŸã«ãããæ¬å»è¬çµæç©ãé©å¿ããã°æ¥µããŠæ
å¹ã«æ²»çãããäºãã§ããã 次ã«å®æœäŸã«ãããã®çºæãæŽã«å ·äœçã«èª¬æ
ããã ïŒå®æœäŸïŒ åèäŸ ïŒ 155åã®ã¢ããé žããæãããTNFã¯ãç¹éæ
60â252496å·ã«èšèŒã®æ¹æ³ã«åŸã€ãŠçµæDNAæ
è¡ã«ãã€ãŠè£œé ããããã®ç¹èš±åºé¡å ¬éå ¬å ±ã®é
瀺å 容ã¯ãåç §ã«ãã€ãŠæ¬æ现æžã«èšèŒããã ãã®ããã«ããŠåŸãããããTNFã®ããè «ç
现èç³»ã«å¯Ÿãã现èå·å®³æŽ»æ§ã¯ã次ã®ããã«ããŠ
è©äŸ¡ããããšãã§ããã ããªãã¡ã1000åã®çŽ°èããåç©Žã«0.2mlã®ç°
ãªãæ¿åºŠã®ããTNFïŒïŒÃ104ããïŒÃ10-4å
äœïŒmlïŒãå«ã96ç©Žãã€ã¯ããã¬ãŒãäžã§å¹é€ã
ããïŒæ¥ä¹è³ïŒæ¥å¹é€ããåŸãTNFãå«ãŸãªã
ç©Žã§å¢æ®ããå¯Ÿç §çŽ°èã¯éå¯ç¶æ ã«ãªãã次ã«ã
çãæ®ã€ã现èã®æ°ãã¡ãã¬ã³ãã«ãŒã®å蟌ã¿ã«
ãã€ãŠæž¬å®ããã çµæã第ïŒè¡šã«ç€ºãã26现è系統ã®ããè «ç现
èã®ãã¡ãïŒç³»çµ±ïŒ15.3ïŒ ïŒã¯éææåæ§ã§ãã
ïŒïŒïŒïŒïŒIC50âŠ1.0åäœïŒmlïŒãïŒç³»çµ±ïŒ23.1ïŒ ïŒ
ã¯é«æåæ§ã§ããïŒïŒïŒïŒIC50âŠ10000åäœïŒ
mlïŒãïŒæ ªïŒ34ïŒ ïŒã¯æåæ§ãããïŒïŒïŒæå¶ç
â§20ïŒ ïŒãïŒæ ªïŒ20.9ïŒ ïŒã¯éæåæ§ã§ãã
ïŒâïŒæå¶çïŒ20ïŒ ïŒããã®ããã«ãããè «ç现è
系統ã®73ïŒ ããããTNFã«å¯ŸããŠæåæ§ã®ãã
ããšã瀺ããããäžæ¹ãæ£åžžäºåäœçŽ°èã«å¯Ÿãã
现èå·å®³æŽ»æ§ã¯èŠ³å¯ãããããŸããæé·åºæ¿äœçš
ãæ°ç³»çµ±ã®æ£åžžçŽ°èã§èŠ³å¯ãããã
ãè¡šã
åèäŸ ïŒ
åèäŸâïŒã«äœ¿çšãããã®ãšåæ§ã«ããŠè£œé ã
ããããTNFã®ããŠã¹ïŒBALBïŒïŒ£ïŒïŒé±éœ¢ïŒ
åã³ã©ããïŒSDïŒïŒé±éœ¢ïŒãžã®éèå æäžåã³
è ¹è å æäžã«ããæ¥æ§æ¯æ§è©Šéšã®çµæã第ïŒè¡šã«
瀺ãã
ããããTNFã®ããŠã¹ïŒBALBïŒïŒ£ïŒïŒé±éœ¢ïŒ
åã³ã©ããïŒSDïŒïŒé±éœ¢ïŒãžã®éèå æäžåã³
è ¹è å æäžã«ããæ¥æ§æ¯æ§è©Šéšã®çµæã第ïŒè¡šã«
瀺ãã
ãè¡šã
å®æœäŸ ïŒ
ä¹³é
žè±æ°ŽçŽ é
µçŽ ãŠã€ã«ã¹ïŒLDVïŒã«ææãã
ããŠã¹ããåŸãããè¡æž ïŒæåæå·¥æ¥æ ªåŒäŒç€Ÿã®
å»è¬ç 究宀ã«ä¿åïŒã10åã«åžéããŠãïŒå¹ã®
BALBïŒcnuïŒnuããŠã¹ã®èäžã«ãããã0.05ml
ãã€æ¥çš®ããããã®ïŒå¹ã®æ¥çš®ããŠã¹ã®ãã¡ãïŒ
å¹ã®ããŠã¹ãç çåŠçå€åãããªãã¡ç€ãåã
ãããã®ç çåŠçå€åãæãããããã®ããŠã¹ã
也ç¬ã¢ãã«ãšããŠäœ¿çšããããšãšããã äžèšåžéè¡æž ã®æ¥çš®åŸ10æ¥ç®ãåããŠã¹ã®ç€ç¶
ã®ç å€éšã®å€§ããã¯ãçŽåŸã§çŽïŒmmã10mmã«ãª
ããäžèšã®åèå®æœäŸã§åŸããã1000ãã3000å
äœã®çšéã®ããTNFããã®ããŠã¹ã«éèå æäž
ããæäžåŸïŒæ¥ç®ã«ããŠã¹ã®ç å€éšäœãèçŒã§èŠ³
å¯ãããçµæã第ïŒè¡šã«ç€ºãã
ããŠã¹ããåŸãããè¡æž ïŒæåæå·¥æ¥æ ªåŒäŒç€Ÿã®
å»è¬ç 究宀ã«ä¿åïŒã10åã«åžéããŠãïŒå¹ã®
BALBïŒcnuïŒnuããŠã¹ã®èäžã«ãããã0.05ml
ãã€æ¥çš®ããããã®ïŒå¹ã®æ¥çš®ããŠã¹ã®ãã¡ãïŒ
å¹ã®ããŠã¹ãç çåŠçå€åãããªãã¡ç€ãåã
ãããã®ç çåŠçå€åãæãããããã®ããŠã¹ã
也ç¬ã¢ãã«ãšããŠäœ¿çšããããšãšããã äžèšåžéè¡æž ã®æ¥çš®åŸ10æ¥ç®ãåããŠã¹ã®ç€ç¶
ã®ç å€éšã®å€§ããã¯ãçŽåŸã§çŽïŒmmã10mmã«ãª
ããäžèšã®åèå®æœäŸã§åŸããã1000ãã3000å
äœã®çšéã®ããTNFããã®ããŠã¹ã«éèå æäž
ããæäžåŸïŒæ¥ç®ã«ããŠã¹ã®ç å€éšäœãèçŒã§èŠ³
å¯ãããçµæã第ïŒè¡šã«ç€ºãã
ãè¡šã
ãè¡šã
第ïŒè¡šã®çµæã¯ã也ç¬ã¢ãã«ã«å¯ŸããTNFã®
å¹æã瀺ããŠãããšèããããã å®æœäŸ ïŒ ããTNFãäžèšåèäŸã«åŸã€ãŠçµæãDNAæ
è¡ã«ãã補é ãããåŸãããçµæãããTNFã
çšããŠãäžèšã®çµæãæã€æ³šå°çšåçµä¹Ÿç¥è£œå€ã
調補ããã çµæ ããTNF ïŒÃ105åäœ ïŒ€âãã³ãããŒã« 30 mg æ£åžžè¡æž ã¢ã«ããã³ïŒããïŒ 10 mg å¡©åãããªãŠã 2.0 mg ãªã³é žäºæ°ŽçŽ ãããªãŠã ã»äºæ°Žåç© 3.9 mg ïŒæ°Žé žåãããªãŠã ã§PH8.0ã«èª¿æŽïŒ å®æœäŸ ïŒ å®æœäŸïŒã§èª¿è£œãããåçµä¹Ÿç¥è£œå€ãïŒmlã®ç
çé£å¡©æ°Žã«æº¶è§£ããããã«ççé£å¡©æ°Žã§åžéãã
æçµå®¹éã100mlãšããã ãã®åžé液ãã70æã®å¥³æ§æ£è ã«æ£è ã®äœè¡šé¢
ç©ïŒm2åœã4.5Ã105åäœã®æäžéã§ïŒæéãããŠ
éèå ã«æç¶æäžããããã®æäžæ¹æ³ã§TNFã
ïŒæ¥éé£æ¥æäžããã ãã®æ£è ã¯25幎é也ç¬ã«èŠãã¿ãçš®ã ã®åžè²©è¬
ïŒOTCè¬ïŒãçšããŠããããå šãå¹æããªãã€
ãããã®åŸããã®ãããªOTCè¬ã®äœ¿çšãïŒå¹Žé
äžæ¢ãããããããäžèšã®ããTNFã«ããæ²»ç
å®äºã®ïŒé±éåŸã«ããã¹ãŠã®çç¶ãæ¶å€±ãããå
æ£è ã¯ãå®å šã«æ²»çãããšèããããã å®æœäŸ ïŒ å°åžžæ§ä¹Ÿç¬æ£è ïŒåãè¿ç±æ§ä¹Ÿç¬æ£è ïŒåã«å®
æœäŸïŒã§èª¿è£œãããè¬å€ãæäžããŠã也ç¬ã«å¯Ÿã
ãå¹æã調ã¹ãã (1) æäžéãšæäžã¹ã±ãžãŠãŒã« å®æœäŸïŒã§èª¿è£œãããåçµä¹Ÿç¥è£œå€ã®èŠå®éã
100mlã®ççé£å¡©æ°Žã«æº¶ããïŒæ¥ïŒåãïŒæéã
ãããŠéèå ã«æç¶æäžãããé£ç¶ïŒæ¥ã®æäžã
ïŒã¯ãŒã«ãšããåã¯ãŒã«ã®éã«ïŒãïŒé±éã®äŒè¬
æéããããååã¯ãŒã«ã®æäžéã¯ïŒäžåäœïŒ
m2ïŒæ¥ã20äžåäœïŒm2ïŒæ¥ãšãããã®åŸã¯æ£è ã®
ç¶æ ãèšåºæ€æ»å€ãªã©ãèæ ®ããŠäž»æ²»å»ã®å€æã«
ããé©å®å¢æžãã10ã50äžåäœïŒm2ïŒæ¥ãæäžã
ããæ²»çäžã¯ä¹Ÿç¬æ²»çã®ããã®ä»ã®åŠçœ®ã¯è¡ããª
ãã (2) å¹æå€å®ã®æ¹æ³ æå¹æ§ã®è©äŸ¡ã¯åã¯ãŒã«ã®æäžååã³æ²»ççµäº
ã®ïŒé±éåŸã«ç®ç¹ã®çŽ æç¶æ ãè¥åç¶æ ãé±å±ç¶
æ ã«ã€ããŠè©äŸ¡ãè¡ããïŒã¯ãŒã«çµäºåŸåç®ç¹ç
ç¶ã«ã€ããŠæ²»çã®ååŸã®æšç§»ãç·åããŠå šè¬æ¹å
床ã 1.èå¹ã2.æ¹åã3.ããæ¹åã4.äžå€ã5.æªåã®ïŒ
段éã«è©äŸ¡ããã (3) çµæ
å¹æã瀺ããŠãããšèããããã å®æœäŸ ïŒ ããTNFãäžèšåèäŸã«åŸã€ãŠçµæãDNAæ
è¡ã«ãã補é ãããåŸãããçµæãããTNFã
çšããŠãäžèšã®çµæãæã€æ³šå°çšåçµä¹Ÿç¥è£œå€ã
調補ããã çµæ ããTNF ïŒÃ105åäœ ïŒ€âãã³ãããŒã« 30 mg æ£åžžè¡æž ã¢ã«ããã³ïŒããïŒ 10 mg å¡©åãããªãŠã 2.0 mg ãªã³é žäºæ°ŽçŽ ãããªãŠã ã»äºæ°Žåç© 3.9 mg ïŒæ°Žé žåãããªãŠã ã§PH8.0ã«èª¿æŽïŒ å®æœäŸ ïŒ å®æœäŸïŒã§èª¿è£œãããåçµä¹Ÿç¥è£œå€ãïŒmlã®ç
çé£å¡©æ°Žã«æº¶è§£ããããã«ççé£å¡©æ°Žã§åžéãã
æçµå®¹éã100mlãšããã ãã®åžé液ãã70æã®å¥³æ§æ£è ã«æ£è ã®äœè¡šé¢
ç©ïŒm2åœã4.5Ã105åäœã®æäžéã§ïŒæéãããŠ
éèå ã«æç¶æäžããããã®æäžæ¹æ³ã§TNFã
ïŒæ¥éé£æ¥æäžããã ãã®æ£è ã¯25幎é也ç¬ã«èŠãã¿ãçš®ã ã®åžè²©è¬
ïŒOTCè¬ïŒãçšããŠããããå šãå¹æããªãã€
ãããã®åŸããã®ãããªOTCè¬ã®äœ¿çšãïŒå¹Žé
äžæ¢ãããããããäžèšã®ããTNFã«ããæ²»ç
å®äºã®ïŒé±éåŸã«ããã¹ãŠã®çç¶ãæ¶å€±ãããå
æ£è ã¯ãå®å šã«æ²»çãããšèããããã å®æœäŸ ïŒ å°åžžæ§ä¹Ÿç¬æ£è ïŒåãè¿ç±æ§ä¹Ÿç¬æ£è ïŒåã«å®
æœäŸïŒã§èª¿è£œãããè¬å€ãæäžããŠã也ç¬ã«å¯Ÿã
ãå¹æã調ã¹ãã (1) æäžéãšæäžã¹ã±ãžãŠãŒã« å®æœäŸïŒã§èª¿è£œãããåçµä¹Ÿç¥è£œå€ã®èŠå®éã
100mlã®ççé£å¡©æ°Žã«æº¶ããïŒæ¥ïŒåãïŒæéã
ãããŠéèå ã«æç¶æäžãããé£ç¶ïŒæ¥ã®æäžã
ïŒã¯ãŒã«ãšããåã¯ãŒã«ã®éã«ïŒãïŒé±éã®äŒè¬
æéããããååã¯ãŒã«ã®æäžéã¯ïŒäžåäœïŒ
m2ïŒæ¥ã20äžåäœïŒm2ïŒæ¥ãšãããã®åŸã¯æ£è ã®
ç¶æ ãèšåºæ€æ»å€ãªã©ãèæ ®ããŠäž»æ²»å»ã®å€æã«
ããé©å®å¢æžãã10ã50äžåäœïŒm2ïŒæ¥ãæäžã
ããæ²»çäžã¯ä¹Ÿç¬æ²»çã®ããã®ä»ã®åŠçœ®ã¯è¡ããª
ãã (2) å¹æå€å®ã®æ¹æ³ æå¹æ§ã®è©äŸ¡ã¯åã¯ãŒã«ã®æäžååã³æ²»ççµäº
ã®ïŒé±éåŸã«ç®ç¹ã®çŽ æç¶æ ãè¥åç¶æ ãé±å±ç¶
æ ã«ã€ããŠè©äŸ¡ãè¡ããïŒã¯ãŒã«çµäºåŸåç®ç¹ç
ç¶ã«ã€ããŠæ²»çã®ååŸã®æšç§»ãç·åããŠå šè¬æ¹å
床ã 1.èå¹ã2.æ¹åã3.ããæ¹åã4.äžå€ã5.æªåã®ïŒ
段éã«è©äŸ¡ããã (3) çµæ
ãè¡šã
ãè¡šã
çäŸïŒã¯19幎éã¡ããã¬ãã»ãŒãçµå£å€ãæçš
ããäžæçã«æ¹åãèªããææããã€ããåçº
ããå ¥é¢æã«ã¯ãé¡ãå«ãå šèº«ã«ä¹Ÿç¬ç å€ãæ¡ã
ã€ãŠããã çäŸïŒãšïŒã¯åŒ·åãªã³ã«ãã³ã¹ããã€ãå¡åžå€
ã®äœ¿çšã«ãæ¹åãèªãããããé¡ãå«ãå šèº«ã«ä¹Ÿ
ç¬ç å€ãæ¡ãã€ãçäŸã§ããã
ããäžæçã«æ¹åãèªããææããã€ããåçº
ããå ¥é¢æã«ã¯ãé¡ãå«ãå šèº«ã«ä¹Ÿç¬ç å€ãæ¡ã
ã€ãŠããã çäŸïŒãšïŒã¯åŒ·åãªã³ã«ãã³ã¹ããã€ãå¡åžå€
ã®äœ¿çšã«ãæ¹åãèªãããããé¡ãå«ãå šèº«ã«ä¹Ÿ
ç¬ç å€ãæ¡ãã€ãçäŸã§ããã
Claims (1)
- ïŒ ä¹Ÿç¬æ²»çã«æå¹ãªéã®è «çå£æ»å åãšãå°ãª
ããšãäžçš®ã®å»è¬æäžå¯èœãªæ äœãåžéå€ããã
ã¯è³Šåœ¢å€ãå«æãã也ç¬æ²»ççšå»è¬çµæç©ã
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29049788A | 1988-12-27 | 1988-12-27 | |
| US290,497 | 1988-12-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH02209812A JPH02209812A (ja) | 1990-08-21 |
| JPH0565492B2 true JPH0565492B2 (ja) | 1993-09-17 |
Family
ID=23116275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1336408A Granted JPH02209812A (ja) | 1988-12-27 | 1989-12-27 | 也ç¬æ²»ççšå»è¬çµæç© |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0377823B1 (ja) |
| JP (1) | JPH02209812A (ja) |
| AT (1) | ATE108331T1 (ja) |
| AU (1) | AU633037B2 (ja) |
| CA (1) | CA2003981C (ja) |
| DE (1) | DE68916777T2 (ja) |
| DK (1) | DK658889A (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5190750A (en) * | 1990-03-09 | 1993-03-02 | Asahi Kasei Kogyo Kabushiki Kaisha | Methods for the treatment of demyelinating disease, uveitis, or graft-versus-host disease using tnf |
| US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| TWI439284B (zh) | 2004-04-09 | 2014-06-01 | Abbvie Biotechnology Ltd | çšæŒæ²»çαçžé倱調çä¹å€éå¯è®åéçæ³ |
| KR101465456B1 (ko) | 2005-05-16 | 2014-11-27 | ì ëžë¹ ë°ìŽì€í í¬ëë¡ì§ 늬믞í°ë | 믞ëì± ë€ë°êŽì ìŒì ì¹ë£ë¥Œ ìí ïœïœïœ ìµì ì ì ì©ë |
| US9605064B2 (en) | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
| CN106729633A (zh) * | 2017-03-03 | 2017-05-31 | äžæµ·å¯ç§çç©å¶è¯æéå ¬åž | äžç§è¿ç€åæ»å åçŽè ç»è¯å¶ååå ¶å¶å€æ¹æ³ |
| US20240108746A1 (en) * | 2020-12-16 | 2024-04-04 | Molecular Partners Ag | Novel slow-release prodrugs |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4879226A (en) * | 1984-04-06 | 1989-11-07 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel human physiologically active polypeptide |
| JPS61292727A (ja) * | 1985-06-20 | 1986-12-23 | Nec Corp | ãâãâã |
| AU2844889A (en) * | 1988-01-22 | 1989-07-27 | Collagen Corporation | Method for suppressing the growth of normal and cancer cells |
-
1989
- 1989-11-27 CA CA002003981A patent/CA2003981C/en not_active Expired - Lifetime
- 1989-12-04 EP EP89122317A patent/EP0377823B1/en not_active Expired - Lifetime
- 1989-12-04 DE DE68916777T patent/DE68916777T2/de not_active Expired - Lifetime
- 1989-12-04 AT AT89122317T patent/ATE108331T1/de not_active IP Right Cessation
- 1989-12-19 AU AU46853/89A patent/AU633037B2/en not_active Ceased
- 1989-12-22 DK DK658889A patent/DK658889A/da not_active Application Discontinuation
- 1989-12-27 JP JP1336408A patent/JPH02209812A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| CA2003981C (en) | 2000-06-13 |
| CA2003981A1 (en) | 1990-06-27 |
| AU4685389A (en) | 1990-07-05 |
| EP0377823A3 (en) | 1991-09-11 |
| JPH02209812A (ja) | 1990-08-21 |
| ATE108331T1 (de) | 1994-07-15 |
| AU633037B2 (en) | 1993-01-21 |
| DK658889D0 (da) | 1989-12-22 |
| DE68916777T2 (de) | 1995-03-16 |
| DK658889A (da) | 1990-06-28 |
| EP0377823B1 (en) | 1994-07-13 |
| EP0377823A2 (en) | 1990-07-18 |
| DE68916777D1 (de) | 1994-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5342613A (en) | Pharmaceutical compositions and use thereof in the treatment of psoriasis | |
| JP3884474B2 (ja) | å ç«å¢åŒ·æ²»çã®ããã®è¬åŠççµæç© | |
| US5202311A (en) | Stabilized fgf composition | |
| JPH05502443A (ja) | 幹现èã®æé·é»å®³æ³ | |
| CA1297004C (en) | Pharmaceutical agent for promoting the recovery of hemopoietic capacity | |
| US5202118A (en) | Method for promoting wound healing using IL-1 | |
| JPH0565492B2 (ja) | ||
| Sotiriou et al. | Etanercept for the treatment of hidradenitis suppurativa | |
| WO1997035609A1 (fr) | Inhibiteur de la neoformation de vaisseaux sanguins renfermant un inhibiteur du mecanisme d'action du facteur tissulaire | |
| US5854271A (en) | Effective method for the amelioration and prevention of tissue and cellular damage | |
| JP2863265B2 (ja) | ã€ã³ã¿ãŒãã€ãã³ïŒã€ã³ããã¿ãŒ | |
| JP4907032B2 (ja) | è¡ç®¡æ°çã®æ²»çã®ããã®æ¹æ³ããã³çµæç© | |
| JP2784401B2 (ja) | æ ¢æ§éªšé«æ§çœè¡ç ã®æ²»çæ¹æ³ | |
| JPH0625010A (ja) | æã¬ã³å€ | |
| US7776818B2 (en) | Methods to treat T-cell disorders using TISF | |
| AU2001261378A1 (en) | Method and composition for the treatment of angiogenesis | |
| AU630341B2 (en) | Topical wound-healing preparations comprising interleukin-1 proteins | |
| JPH03236328A (ja) | 也ç¬æ²»ççšå»è¬çµæç© | |
| JPH0618779B2 (ja) | é è¡æ©èœå埩ä¿é²å€ | |
| JP2838867B2 (ja) | 幹现èå¢æ®ä¿é²å€ | |
| JP2010509364A (ja) | åµå·æ²»çã«ããã䜿çšã®ããã®ïœïœâïŒïŒïœ | |
| JPH0517367A (ja) | 骚ç²é¬çæ²»çå€ | |
| JPH03236329A (ja) | ãªã³ãããã·ã³ãå«æãã也ç¬æ²»ççšå»è¬çµæç© | |
| Jackson et al. | Activated protein C to treat chronic wounds | |
| JP3167714B2 (ja) | ç¥çµçŽ°èä¿è·å€ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090917 Year of fee payment: 16 |
|
| LAPS | Cancellation because of no payment of annual fees |